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Kurzfassung der Arbeit 
Oxytocin ist ein Neurohormon, welches eine wichtige Rolle bei sozialen Verhaltensweisen spielt. 
Eine Fehlregulation des Oxytocin Systems kann daher zu tiefgreifenden Konsequenzen für die 
mentale Gesundheit führen. Solche Fehlregulationen können den Liganden selbst betreffen, 
wobei eine generell erniedrigte Konzentration bei einer Patientengruppe, die an einer Form von 
Autismus leidet, festzustellen ist. Des Weiteren konnte eine genetische Komponente, 
sogenannte Einzelnukleotidpolymorphismen (engl. single nucleotide polymorphisms, kurz SNPs), 
im Oxytocin Rezeptor Gen mit Autismus assoziiert werden. Aufgrund dieser Assoziationen und 
seiner vielversprechenden prosozialen und angstlösenden Wirkung, wird bereits seit längerem 
intensiv am Einsatz von Oxytocin als Therapeutikum bei psychosozialen Störungen geforscht. In 
den bestehenden Studien zeichnet sich jedoch ein eher kontroverses Bild ab. Während die 
Verabreichung einer einzelnen Dosis Oxytocin, das über ein Nasenspray appliziert wird, meist zu 
positiven Effekten in den Tests führte, kam es bei der wiederholten Gabe über einen längeren 
Zeitraum oft zu keiner Verbesserung der Symptome. Um eine langfristig sichere Therapie mit 
Oxytocin gewährleisten zu können, oder mögliche Alternativen zu identifizieren, müssen die 
molekularen Wirkmechanismen von Oxytocin und des Oxytocin Rezeptors genauer untersucht 
werden. 
In meiner Doktorarbeit habe ich verschiedene Zelllinien verwendet, um die daran beteiligten 
Signalwege und zellulären Prozesse aufzuklären. So konnte ich zeigen, dass Oxytocin die 
Morphologie von Neuronen beeinflussen kann, indem es zu einer Änderung der Neuritenlänge 
führt. Ob sich dies in einer Verkürzung oder Verlängerung der neuronalen Fortsätze äußert, ist 
von der Expression und Aktivierung des Transkriptionsfaktors Myocyte Enhancer Factor (MEF) 2A 
abhängig. In diesem Zusammenhang konnte ich zwei Faktoren identifizieren, welche die Aktivität 
von MEF2A regulieren: den MAP Kinase Signalweg und die Phosphatase Calcineurin.  
Zudem konnte ich durch einen Knock-out von MEF2A dessen zentrale Rolle bei der Funktion von 
Mitochondrien mit direkter Konsequenz für die Energiebereitstellung in Neuronen belegen.  
Des Weiteren habe ich die Auswirkungen einer genetischen Variante des Oxytocin Rezeptors, des 
SNPs rs4686302, der in verschiedenen Studien mit Autismus, Empathie und sozialen 
Kognitionsstörungen assoziiert wurde, auf molekularer Ebene untersucht. Durch den 
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unmittelbaren Vergleich zweier humaner Zelllinien, wobei eine die SNP- und die andere eine 
Wildtyp-Variante des Rezeptors exprimierte, konnte ich Abweichungen gezielt analysieren. 
Durch eine Sequenzierung des Genoms fiel dabei eine Duplikation des Oxytocin Rezeptor Gens 
in der SNP-Zelllinie als weitere Variation auf. Auf Basis der beiden genetischen Varianten, konnte 
ich Unterschiede hinsichtlich der Rezeptorstabilität, des Calcium- und MAP Kinase Signalweges 
sowie eine umfassend differentielle Genregulation aufzeigen. 
Zusammenfassend konnte ich durch meine Arbeit das Wissen über die zellulären Effekte von 
Oxytocin und die Auswirkungen von genetischen Variationen, die das Oxytocin Rezeptor Gen 
betreffen, erweitern und somit zu einem besseren Verständnis des Oxytocin Systems beitragen. 
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1 General introduction 
This section is intended to convey and expand biological principles, basics and functions relevant 
to my thesis. It forms the basis for the introductions in 2.2, 3.2 and 4.2.  
1.1 Oxytocin 
The neuropeptide oxytocin (OT) enjoys a good reputation, reflected by its common description 
as the love or cuddle hormone. Released during physiological processes that are usually positively 
associated like uterus contraction during birth, milk ejection during breast-feeding, and orgasms, 
it promotes feelings of love, trust, bonding and well-being (Jurek and Neumann, 2018). Hence, 
besides its important role in reproduction, it is involved in many social actions and interactions 
like mother-child bonding, caregiving and trusting behavior, empathy, pair bonding, sexual 
behavior, as well as anxiety and aggression. 
In accordance with this overall beneficial picture, there seems to be a positive correlation 
between our states of mental health and endogenous OT levels. People within the first stages of 
a romantic relationship have higher levels of OT (Schneiderman et al., 2012; Acevedo et al., 2012). 
In contrast, low levels of OT have been found in patients suffering from autism spectrum disorder 
(ASD) or depression (Parker et al., 2017; Yuen et al., 2014). 
Given these correlations, and because of its prosocial and anxiolytic effects, it has been suggested 
as a promising therapeutic agent for many psychosocial disorders, such as anxiety disorder or 
ASD. Delivered through a nasal spray, OT raised hopes as a non-invasive treatment option to help 
people who avoid social interaction and persistently experience fear and mistrust. 
However, there is a general inconsistency occurring in studies testing its potential as treatment, 
especially when tested in long-term administration regimens. Comparing its effects on anxiety in 
rodents upon acute single-dose versus chronic long-term administration, the thin line between 
advantages and risks becomes quite apparent. An acute infusion of synthetic OT directly into the 
paraventricular nucleus (PVN) of male and female rats increased the time they spent in the open 
arms or lit compartment in the behavioral tests of the elevated plus maze or light dark box, 
reflecting a decreased level of anxiety (Blume et al., 2008; Jurek et al., 2012). A chronic treatment 
with 10 ng/h intracerebroventricular OT via osmotic minipumps however, induces anxiogenesis 
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in male mice (Peters et al., 2014) and, in combination with a mild stressor, in male and female 
rats (Winter et al., 2020). 
A similarly controversial picture of OT emerges from studies examining its efficacy and safety as 
treatment for ASD patients. ASD is a neurodevelopmental disorder that affects communication 
and social behavior. People who suffer from ASD have difficulties interacting with other people 
and show impaired communication skills. For example, they do not to look at or listen to people 
or show facial expressions and movements not matching with what is being said. They often show 
restricted interests and repetitive behaviors, and slight changes in their daily routine can make 
them feel upset and extremely irritated (Freitag and Konrad, 2014). Those psychological traits 
hamper their abilities to function properly in school, work, and private life. Upon administration 
of one single dose of OT, several studies confirmed improvements in a wide range of social 
behaviors, as well as a reduction of repetitive behaviors (Watanabe et al., 2014; Aoki et al., 2014). 
However, as an acceptable treatment for ASD, OT must have prolonged efficacy. While some 
studies claim considerable improvements in key symptoms of ASD by long-term administration 
of OT (Parker et al., 2017; Tachibana et al., 2013), other studies found no improvements 
(Guastella et al., 2015; Dadds et al., 2014). 
In order to understand the opposing effects provoked by the same compound, we have to 
develop a deeper understanding of the molecular underpinnings and functions of the OT system. 
OT consists of the nine amino acids: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, and is produced in 
the supraoptic nucleus (SON), accessory nuclei, and PVN of the hypothalamus (Jurek and 
Neumann, 2018). It can be released from magnocellular neurons by axonal and somatodendritic 
release, and into the periphery via axonal projections. Due to its similarity to the closely related 
nonapeptide vasopressin, OT can bind to the three vasopressin receptor subforms V1a, V1b and 
V2, although with reduced affinity compared to the main target of the natural ligand – the 
oxytocin receptor (Chini and Manning, 2007). 
1.2 Oxytocin receptor 
The oxytocin receptor (OTR) belongs to the family of G protein coupled receptors (GPCRs), 
consisting of seven transmembrane helices, three extracellular as well as three intracellular loops 
(Gimpl and Fahrenholz, 2001). In humans, the OTR is encoded by the OTR gene located on 
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chromosome 3 (3p25–3p26x·2) as an inverted 17-kb single-copy gene and consists of four exons 
and three introns. The coding sequence encompasses only the major part of Exon 3 and the first 
part of Exon 4 (Peter et al., 1995). The OTR forms homodimers and heterodimers with other 
GPCRs, which consequently results in an enhanced activation of receptor-coupled signaling 
cascades (Busnelli et al., 2016). 
In the periphery, the OTR is expressed by the myoepithelial cells of the mammary gland, in both, 
the myometrium and endometrium of the uterus, in cardiomyocytes of the heart, dermal 
fibroblasts as well as osteoclasts and osteoblasts. In the mammalian brain, the OTR is expressed 
throughout many brain regions including the hypothalamus, prefrontal cortex, hippocampus, and 
amygdala (Jurek and Neumann, 2018). However, the OTR is generally expressed at low levels, 
rendering its detection in some regions quite challenging (Freund-Mercier et al., 1994).  
In addition, the OTR membrane expression depends on ligand availability, since an increased 
ligand availability over prolonged periods can result in receptor desensitization and 
internalization. The desensitization of the OTR is initiated by the G protein-coupled receptor 
kinase 2, which phosphorylates and primes the OTR for subsequent ß-arrestin binding. Arrestin 
binding to the OTR induces uncoupling from the G proteins, blocks further signaling cascades and 
targets the OTR for internalization. The OTR is internalized in a clathrin pit-dependent mechanism 
and intracellularly stored in “Ras-related in brain 4/5”-vesicles that get recycled after four hours 
as shown in HEK293 cells (Conti et al., 2009). Interestingly, selective OTR ligands like the agonist 
carbetocin have been shown to induce β‐arrestin‐independent internalization without recycling 
back to the plasma membrane (Passoni et al., 2016). 
These processes, resulting in a reduced membrane expression, bear consequences for a therapy 
that would encompass repeated daily intranasal applications of OT over a longer period. 
Besides the natural ligands OT and vasopressin, there are several synthetic OTR agonists and 
antagonists that can exclusively activate or block the OTR based on their selectivity and affinity. 
The OTR itself can occur in a high- or low-affinity state, whereby the conversion between the two 
affinity states is reversible (Gimpl and Fahrenholz, 2001; Wiegand and Gimpl, 2012). Two 
components, cholesterol and magnesium, have been found to act as strong allosteric modulators, 
affecting the stability and binding of ligands to the OTR. 
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Very recently, the crystal structure of the human OTR has been solved and published in a pre-
print (Waltenspühl Y. et al., 2020). In this study, the authors also localized the binding sites for 
cholesterol and magnesium, providing a structural understanding of the stabilization-effects for 
the OTR, thereby constituting a giant leap for a better understanding of the OT system and for 
the future development of therapeutic compounds targeting the receptor.  
As a GPCR, the OTR is coupled to a trimeric complex of G proteins comprising a Gα and a Gβ/γ 
unit, which are separated from each other upon ligand binding. Depending on the activated Gα 
subtype, which can differ between tissues and cell types, the outcome can be either inhibitory or 
excitatory and different downstream signaling cascades get activated (Figure 1). 
1.3 Oxytocin receptor-coupled signaling 
Upon OTR activation there is an increase in intracellular Calcium (Ca2+) caused by a Ca2+ influx 
from the extracellular space via several Ca2+ channels like transient receptor potential (TRP) 
cation channels including the canonical forms TRPC1 and TrpC3-TRPC6 as well as the vanilloid 
forms TRPV2 and TRPV4, but also voltage-gated Ca2+ channels (van den Burg et al., 2015; 
Murtazina et al., 2011; Shlykov et al., 2003; Ulloa et al., 2009; Ying et al., 2015). In addition, OTR 
activation provokes a release of Ca2+ from intracellular stores (Sanborn et al., 1998; Tobin et al., 
2011). Upon G protein activation, phospholipase C (PLC) gets activated cleaving phospholipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). Those two products are important second messenger molecules that control 
several cellular processes and serve as substrates for other signaling molecules. IP3 is a soluble 
signaling molecule that diffuses through the cytoplasm to the endoplasmic reticulum, where it 
binds to its receptor, a Ca2+ channel, inducing the release of Ca2+ from the endoplasmic reticulum 
lumen into the cytosol. DAG, the second product of PLC activation, remains in the plasma 
membrane and mediates the activation of protein kinase C (PKC). The resulting elevation in 
cytoplasmatic Ca2+ levels from intracellular and extracellular sources is essential for several OTR-
coupled signaling pathways.  
The basal intracellular Ca2+ concentration and evoked Ca2+ signals have to be tightly regulated 
since important aspects of cell function are dependent on this homeostasis, including gene 
expression, and energy metabolism (Clapham, 2007). These cell functions depend on Ca2+ signal 
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propagation to the specific organelles like the mitochondria for synchronization of the ATP 
generation with cell function, or the nucleus for gene regulatory events (Zhang et al., 2009; 
Griffiths and Rutter, 2009). Dysregulations in Ca2+ signaling can have severe consequences 
including cell necrosis or apoptosis. 
The set of downstream signaling cascades comprise the already mentioned PKC, several CaMK 
subforms, the phosphatase Calcineurin (CaN), as well as the mitogen-activated protein kinase 
(MAPK) pathway. However, not only intracellular Ca2+ leads to the activation of this pathway. At 
the same time, a cross-reaction of receptor tyrosine kinases like the epidermal growth factor 
(EGFR) has been observed eventuating in the recruitment of the membrane-associated proto-
oncoprotein GTPase Rat sarcoma (Ras) (Blume et al., 2008). Ras in turn functions as an initiator 
of the MAPK pathway with its kinases MAP kinase kinase 1 and 2 (MEK1/2) and extracellular 
signal regulated kinase 1/2 (ERK1/2). Besides that, the OTR has also been linked to an activation 
of the MAPKs p38 and ERK5 in myometrial cells, but their coupling and downstream targets in 
neuronal cells remain to be elucidated (Devost et al., 2008; Brighton et al., 2011). 
All those signaling pathways converge on transcription factors regulating the transcription of 
their target genes. The OT-induced targets we have mostly focused on are the transcription factor 
CREB, which is involved in spatial memory formation and CRF gene transcription (Tomizawa et 
al., 2003; Jurek et al., 2015) and the myocyte enhancer factor (MEF) 2 (Meyer et al., 2018; Meyer 
et al., 2020). The MEF2 family of transcription factors consists of four isoforms, namely MEF2A, -
2B, -2C and -2D. All subforms share a common genetic structure consisting of an N-terminal DNA 
binding domain, the MEF2 domain, and a COOH-terminal transcriptional regulatory domain, 
whose activity is orchestrated by multiple posttranslational modifications. The phosphorylation 
status of the MEF2 proteins regulates the gene transcription and thereby determines the function 
of the respective biological process. In case of MEF2A, phosphorylation of the protein at the sites 
serine (S) 387, threonine (Thr) 312, and Thr319 stimulates gene transcription, whereas 
phosphorylation at S408 has an inhibitory outcome (Potthoff and Olson, 2007). 
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Figure 1. Overview of oxytocin receptor (OTR)-coupled signaling pathways in neurons. Binding of oxytocin to the 
OTR activates transient receptor potential vanilloid type 2 (TRPV2) channels and subsequent Calcium (Ca2+)-
dependent cascades including protein kinase C (PKC), Ca2+/calmodulin-dependent kinase (CaMK) I, II, IV, and 
calcinueurin (CaN). OTR activation also induces transactivation of the epidermal growth factor receptor (EGFR) and 
subsequent MAPK activation involving the extracellular signal regulated kinase (ERK) 1/2, ERK5, and p38. The 
signaling pathways converge on the transcription factor cyclic AMP responsive element binding protein (CREB) and 
cyclic-AMP-regulated transcriptional coactivators (CRTC) as well as myocyte enhancer factor 2 (MEF2), leading to 
the transcription of target genes. Adapted from (Jurek and Neumann, 2018). 
 
The MEF2 proteins show distinct but overlapping sets of functions (Pon and Marra, 2016). They 
play an important role in muscle and cardiac cell development and affect cell differentiation, 
proliferation, migration, apoptosis, and metabolism (Potthoff and Olson, 2007). Furthermore, 
they are implicated in fundamental cellular processes in the central nervous system including 
neuronal morphology, survival, connectivity, plasticity, and metaplasticity (Akhtar et al., 2012; 
Chen et al., 2012; Meyer et al., 2018; Meyer et al., 2020). These processes are strongly 
intertwined since neuronal connectivity and plasticity are regulated by adaptations of the cellular 
morphology including neurite outgrowth, synapse formation, and cell adhesion, depending on 
the temporary requirements. Changes in the cellular morphology, like branching dendrites and 
axons or the generation of dendritic spines mediated via the cytoskeleton, serve to make wiring 
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among networks more efficient (Chklovskii, 2004). Therefore, the balance of these processes is 
essential for proper cognitive function and has to be maintained. 
Dysfunctions concerning the MEF2 family have been associated with ASD, mental retardation, 
amyotrophic lateral sclerosis, Alzheimer’s, and Parkinson’s disease (Morrow et al., 2008; Lipton 
et al., 2009; Tu et al., 2017). 
Thus, a balanced activity of the OT system is crucial for essential behavioral responses. Genetic 
or epigenetic factors may influence this by contributing to individual differences in behavioral 
responses. Among the genetic factors that might lead to a predisposition for the development of 
certain psychosocial disorders like ASD are single nucleotide polymorphisms in the OTR gene 
(Bakermans-Kranenburg and van Ijzendoorn, 2014). 
1.4 Single nucleotide polymorphisms in the oxytocin receptor gene 
A single nucleotide polymorphism (SNP) is a variation in a single nucleotide occurring at a specific 
position in the genome, which is carried by more than 1 % of individuals in a population. Of the 
4-5 million SNPs mapped so far in the human genome, just a few percent are within protein-
coding genes, while the majority lies within regulatory or inactive regions (Freedman et al., 2011; 
Edwards et al., 2013). Depending on their location in coding or non-coding sequences within a 
given gene, they can affect the protein in various ways. For instance, SNPs outside the coding 
sequence like introns, promoters, untranslated regions, and exonal non-coding regions can 
regulate the gene splicing or transcription factor binding. When they are located within the 
coding region of an exon, they can be either synonymous or non-synonymous. Synonymous SNPs 
do not affect the protein sequence whereas non-synonymous SNPs result in an amino acid 
change in the protein. A change in the amino acid sequence affects the protein structure and its 
function. Thus, non-synonymous SNPs are believed to have the highest impact on the phenotype. 
How non-synonymous SNPs could affect the phenotype is not fully understood, however, 
mutations present in genes can affect transcriptional and translational output (Robert and 
Pelletier, 2018). 
Genome-wide association studies (GWAS) that identify genetic variants linked with a specific 
phenotype, e.g. a disease, are a quite recent achievement, further facilitated by the declining 
costs and proceeding methods of high-throughput sequencing. SNP detection developed fast and 
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has become a major part of modern medical research. Each SNP that has been identified receives 
a reference ID number and can be found in online databases such as dbSNP hosted by the 
National Center for Biotechnology Information (NCBI) or SNPedia. The gain of knowledge by SNP 
studies contributes to the identification of avoidable risks or tailor-made prevention leading to 
personalized life-style profiles and diet recommendations provided by companies. They are 
promoted as a big step towards personalized medicine since SNPs cannot only determine one’s 
susceptibility to certain diseases but also the success of a therapy.  
GWAS have revealed several genetic variants of the OTR that have been associated with various 
traits and behaviors in humans, psychosocial disorders or pathological conditions (International 
HapMap et al., 2007) (Figure 2).  
 
 
Figure 2. Overview of single nucleotide polymorphisms (SNPs) in the human oxytocin receptor (OTR) gene on 
chromosome 3 consisting of four exons and three introns. SNP IDs are given in orange boxes below and chromosomal 
positions indicated in numbers above. Only SNPs that have been associated with psychological or psychiatric traits 
have been included. Data extracted from ensembl data base. Adapted from (Jurek and Neumann, 2018). 
 
The associated features comprise social behavior and communication, cognition, parental care, 
empathy, and symptoms that are allocated e.g. to attention deficit hyperactivity disorder, 
depression or schizophrenia (Walum et al., 2012; Klahr et al., 2015; Skuse et al., 2014; Weisman 
et al., 2015). Most of the associations in the OTR gene however, have been related to ASD. 
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Therefore, besides dysregulated plasma OT concentrations, OTR SNPs have been promoted as 
possible biomarkers for social impairments in ASD (Parker et al., 2017).  
However, although intensely studied, the association between ASD and SNPs in the OTR gene 
remains controversially discussed. Several studies show contradictory results about the presence 
of a specific SNP and its contribution to the etiology of a given disorder.  
Several associations of SNPs could not be replicated and often disappeared after correction for 
multiple comparisons (Campbell et al., 2011; Tansey et al., 2010; Wermter et al., 2010). An 
example repeatedly reported in this context is rs237887, where the association was found to be 
dependent on the behavioral tests performed. While few studies found the ‘A’ allele of rs237887 
was not associated with ASD diagnosis, others confirmed an association with e.g. reduced face-
recognition memory in families with an autistic child or impaired altruism in two separate 
behavioral tasks (Skuse et al., 2014; Verhallen et al., 2017). 
It is not known whether disruptions in oxytocinergic signaling contribute to a risk for ASD or are 
associated with variability in social deficiency in ASD. 
Since intranasally applied OT is considered to act through the OTR, the efficacy and inconsistent 
findings on symptom improvement might depend on SNPs in the OTR gene that might cause 
some loss or gain of functions. However, there are just very few studies about the functional 
significance of SNPs (Fueg et al., 2019; Furman et al., 2011). Therefore, studies regarding the 
molecular effects of SNPs, their role and possible combinatory effects are greatly needed to 
bridge the gap between genetic association and function. 
1.5 Aim of the thesis 
The aim of my thesis was, to study the molecular mechanisms and effects following OTR 
activation in order to understand the cellular changes in the context of psychosocial disorders 
and emotional dysfunctions. During the course of my PhD, I studied the OT system in vitro 
focusing on various intracellular aspects. After stimulating cells with OT, I identified activated 
signaling pathways and their consequences on cellular processes like neuronal morphology, 
neuronal connectivity, cell viability, mitochondrial function, and ATP production (Figure 3). 
Further, considering common genetic aberrations in the OTR gene leading to different OTR 
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protein variants, I assessed how this affects the receptor stability, a selection of already known 
coupled signaling cascades and the expression of downstream target genes.  
 
 
Figure 3. Aim of the thesis. This thesis aimed to assess the oxytocin (OT) -induced effects on signaling cascades 
including the mitogen-activated protein kinase (MAPK) pathway as well as calcium (Ca2+) signaling and downstream 
activated transcription factors like the myocyte enhancer factor (MEF) 2. Additionally, the aim was to assess the 
consequences for various cellular parameters such as mitochondria function, ATP production, the expression of 
target genes, cellular morphology and viability as well receptor stability, also with regard to the activated oxytocin 
receptor (OTR) variant. The schematic art pieces used in this figure were provided by Servier Medical art 
(http://servier.com/Powerpoint‐image‐bank). Servier Medical Art by Servier is licensed under a Creative Commons 
Attribution 3.0 Unported License. 
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2 Oxytocin alters the morphology of hypothalamic neurons via the 
transcription factor myocyte enhancer factor 2A (MEF2A) 
2.1 Abstract 
OT has gained attention not only as anxiolytic drug and as potential treatment option for autistic 
children; it also acts as a growth and differentiation factor in neuronal cells. While behavioral 
effects of OT have been studied in detail, knowledge about the cellular effects of OT is relatively 
sparse. In this study, we present evidence for three hypotheses: 1) OT leads to neurite retraction 
in hypothalamic neurons via the OTR 2) The transcription factor MEF2A is a central regulator of 
OT-induced neurite retraction, and 3) The MAPK pathway is critical for OT-induced MEF2A 
activation. Incubation of rat hypothalamic H32 cells with 10 nM to 1 μM OT, vasopressin, and the 
specific OTR agonist TGOT, over the course of 12 h resulted in a time-dependent, significant 
retraction of neurites. In addition, the size of the nuclear compartment increased, whereas the 
overall cell size remained unchanged. OT treatment for 10 h increased the cellular viability 
significantly, and this effect could be blocked by a specific OTR antagonist, providing evidence for 
a specific and pro-active effect of OT on neurite retraction, and not as an unspecific side effect of 
apoptosis. The molecular mechanism that controls OT-induced neurite retraction includes a 
reduced phosphorylation of the transcription factor MEF2A at S408. This dephosphorylation is 
under the control of the OTR-coupled MAPK pathway, as blocking MEK1/2 by U0126 inhibited 
MEF2A activation and subsequent neurite retraction. The siRNA-mediated knockdown of MEF2A 
prevented the OT-induced neurite retraction, providing direct evidence for a role of MEF2A in 
morphological alterations induced by OT treatment. In summary, the present study reveals a 
previously unknown OTR-coupled MAPK-MEF2A pathway, which is responsible for OT-induced 
neurite retraction of hypothalamic neurons. 
2.2 Introduction 
The neuropeptide OT is a central modulator of complex socio-emotional behavior, such as 
anxiety, affective behavior, and aggression (Jurek and Neumann, 2018; Kosfeld et al., 2005; 
Kumsta and Heinrichs, 2013; Neumann and Landgraf, 2012). The molecular underpinnings of 
these behavioral effects are largely unknown. The OTR is almost ubiquitously expressed in the 
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central nervous system (Grinevich et al., 2016; Jurek and Neumann, 2018), most notably in the 
hypothalamus, the site of OT synthesis. The OTR is a G protein coupled receptor, whose activation 
by its ligand leads to promiscuous coupling to various Gα-proteins (Busnelli and Chini, 2018), Ca2+ 
release from intracellular stores (Tobin et al., 2011) and subsequent influx of Ca2+ from the 
extracellular space through TrpV2 channels (van den Burg et al., 2015). These G proteins in 
combination with the Ca2+ influx activate several signaling cascades, most prominently the MAP 
kinase pathway, with its main kinases MEK1/2 and ERK1/2 (Blume et al., 2008; Jurek et al., 2012). 
MAP kinase pathways have been associated with neurite outgrowth (Won et al., 2015; Kang et 
al., 2011; Xu et al., 2015), anxiety (Blume et al., 2008; Jurek et al., 2012; Borges et al., 2015), and 
memory formation (Tomizawa et al., 2003). Downstream effectors of ERK1/2 are the 
transcription factors CREB (Tomizawa et al., 2003; Jurek et al., 2015) and MEF2 (Devost et al., 
2008). MEF2 was originally defined as a muscle-specific factor that binds an A/T-rich element in 
the promoter of target genes (Gossett et al., 1989), and was later found to be ubiquitously 
expressed in all types of tissue, especially in the brain (Dietrich, 2013). One central function of 
MEF2 is the regulation of neuronal morphology, i.e. neurite outgrowth (Flavell et al., 2006), either 
via gene inhibition or activation. Among the MEF2-regulated genes are immediate-early genes 
such as c-JUN and NUR77, as well as regulators of neuronal activity, such as ARC, SYNGAP, 
HOMER1A, and BDNF (Flavell et al., 2006). Consequently, MEF2 represents a central factor for 
the regulation of neurite outgrowth, synapse formation, and, if dysregulated, was found to play 
a key role in the development of ASD (Potthoff and Olson, 2007). Here, the functions between 
OT and MEF2 may overlap, as both are implicated in ASD (Parker et al., 2014; Bales et al., 2013) 
and neurite outgrowth (Lestanova et al., 2016; Lestanova et al., 2017). However, the literature 
describes inconsistent effects of OT on cellular morphology. For instance, OT bursts during milk 
letdown lead to retraction of glial cells in rat dams (Langle et al., 2002; Theodosis, 2002), and in 
vitro application of synthetic OT leads to neurite retraction in hippocampal neurons (Ripamonti 
et al., 2017); however, when tested in human SH-SY5Y neuroblastoma cells and glial U-87MG cell 
lines, OT leads to neurite outgrowth (Lestanova et al., 2016; Lestanova et al., 2017). This 
outgrowth seems to be executed by the rearrangement of actin filaments to the apical part of 
neuronal cones and paralleled by changes in expression of the intermediate filament protein 
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nestin, which is implicated in axon growth (Bakos et al., 2012). It is unknown so far, whether the 
differential effects of OT on neuronal and glial cells, i.e. neurite retraction (Ripamonti et al., 2017) 
or neurite outgrowth (Lestanova et al., 2016), are caused by the use of different doses of OT, by 
the use of different cell types (primary neurons or cell lines), different species (mouse, rat, human 
cells), or even the sex of the cell donor (Li et al., 2016). Therefore, it is of paramount importance 
to choose a physiological relevant model to investigate the effects of OT on cell morphology. As 
OT and the OTR are expressed in the hypothalamus of the brain (Jurek et al., 2015; Freund-
Mercier et al., 1994; Dabrowska et al., 2011), rat hypothalamic neurons (H32 cells) provide a 
suitable in vitro model to provide a full characterization of the cellular response to OT. A full 
characterization of the cellular response is pivotal, especially since the OT molecule is known to 
bind the receptor of the related nonapeptide vasopressin as well at higher concentrations, with 
the result of mixed OTR and vasopressin receptor-mediated cellular effects. In turn, vasopressin 
can also bind the OTR, which could result in a similar effect of both peptides on cellular 
morphology. In order to circumvent any non-OTR-mediated effects we made use of specific 
antagonists and agonists of the OTR such as Thr4, Gly7-OT (TGOT), an OT agonist with a 16.000 
times higher affinity for the rat OTR than for the rat vasopressin receptor (Chini et al., 2008; 
Manning et al., 2008); however, this OTR-specificity is lost in cells of human origin (Chini et al., 
2008). The advantage of OTR-specificity of TGOT in rat cells, in combination with the 
hypothalamic origin, convinced us to conduct comprehensive morphological studies regarding 
OT's cellular effects in H32 cells. In summary, we aim to contribute to the clarification of the 
effects of OT on cellular morphology and identify the intracellular signaling cascades that control 
the observed morphological alterations. In order to do so, we tested the hypothesis that the 
transcription factor MEF2 is a key regulator of neurite retraction in hypothalamic neurons, and 
that its activation is dependent on the OTR-coupled MEK1/2-ERK1/2 pathway. 
2.3 Materials and methods 
2.3.1 Cell culture 
Rat hypothalamic H32 cells (passages 15–30) were cultured in 1:1 Dulbecco's Minimum Essential 
Medium/Ham F12 Medium (growth medium). The growth medium was supplemented with 10 % 
heat inactivated fetal bovine serum (Capricorn, Germany), 0.1 % nonessential amino acids, 100 
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U/ml gentamycin (both Invitrogen, Germany) in humidified atmosphere containing 5 % CO2 at 37 
°C. Passaging was performed at least once a week by gentle trypsination. 
2.3.2 Cell viability assay 
Cellular viability was tested using the PrestoBlue Cell Viability Assay (A13261, Invitrogen) 
according to manufacturer's protocol. Briefly, 20 × 103 cells per well were seeded the day before 
the test in a 96-well-plate in growth medium. The volume of the treatment and serum-free 
medium (DMEM/F12 + 0.1 % BSA, sterile filtered) for the stimulation was calculated to a total of 
90 μl per well. 10 μl of PrestoBlue Reagent were added directly to the cells, incubated for 30 min 
to 2 h, before reading the fluorescence intensity with a FluoStar Plate reader (BMG). Optimal 
DMSO concentrations as solvent for the U0126 MAPK inhibitor (Sigma Aldrich) were determined 
by a separate dose response experiment. 
2.3.3 Protein isolation 
For the extraction of proteins from adherent H32 cells, medium was removed and cells were 
washed with PBS supplemented with Protease and Phosphatase inhibitors (PI, A32959, Thermo 
Fisher). Cells were scraped, centrifuged, and the cell pellet was resuspended in 100 μl RIPA lysis 
buffer (R0278, Sigma Aldrich) with HALT Inhibitor and EDTA (78444, Thermo Fisher) to extract 
whole cell lysate. 
2.3.4 Western blot 
Between 5 and 30 μg of whole cell extract and an equivalent volume of 4× loading buffer (2.4 ml 
TRIS, 0.8 g SDS, 4 ml 100 % Glycerol (AppliChem), 0.01 % Bromphenol Blue (Sigma Aldrich), 1 ml 
Mercaptoethanol and 2.8 ml H2O) were applied to 12 % Mini and Midi PROTEAN or Criterion TGX 
Stain-free gels (456–8044 and 5678045, BioRad). Western blot analysis was performed using the 
Stain-free total protein method (BioRad) as loading control, according to the manufacturer's 
protocol. Stain-free gels contain trihalo compounds that covalently bind to tryptophan residues 
in proteins when exposed to UV light. By that, the proteins are made fluorescent directly in the 
gel, allowing the immediate visualization of proteins at any point during electrophoresis or 
blotting and permitting the user to normalize bands to total protein in each lane. This technology 
circumvents the problematic use of housekeeping proteins as loading controls on western 
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blots. In order to detect activated MEF2, a phospho-specific MEF2A S408 (CSB-PA000728, 
Flarebio Biotech) antibody was used at 1:5000 in 5 % BSA concentration. A MEF2A total antibody 
(#TA307807, OriGene, 1:5000 in 5 % BSA) was used to detect total MEF2A levels. Changes in 
expression levels were analyzed measuring grey density in a semi-automatic manner by Image 
Lab Software (Version 6.0, BioRad). 
2.3.5 Cell stimulations 
Cells were grown in the presence or absence of 10 nM, 100 nM, or 1 μM of OT (Bachem, 
Germany) for 0, 2, 4, 8, 10, and 12 h in cell culture dishes or 3-part chamber slides (BD Falcon, 
Germany). A separate experiment was performed using cells incubated with [Thr4, Gly7]-oxytocin 
(TGOT, 100 nM, Bachem) or vasopressin (100 nM, Bachem). When inhibitors (U0126, Sigma 
Aldrich) or OTR antagonist des-Gly-NH2d(CH2)5[Tyr(Me)2Thr4]-OVT (kindly provided by M. 
Manning) were used, cells were incubated in serum free medium for 1 h, pretreated with the 
inhibitor or VEH (H2O or DMSO) for 10 min, and stimulated with the according treatment. To 
assess the role of MEF2A, H32 cells were transfected with small interfering RNA (siRNA). 3 unique 
27mer MEF2A siRNA duplexes (Origene, SR504191; for sequences see Table 1) and Lipofectamine 
RNAiMAX Reagent (Invitrogen), diluted in OptiMEM were added for 72 h in a concentration of 1 
nM siRNA. To verify the specificity of the knockdown, additional wells were transfected with a 
scrambled siRNA CONTROL (siCTRL, SR30004). Effects of OT were assessed via co-stimulation 
with 100 nM OT for 24 h. 
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Table 1. MEF2A siRNA duplex sequences. All three duplexes were mixed 1:1 and added for transfection. 
siRNA Duplex sequence 
SR504191A rGrArArCrUrUrUrCrUrGrCrArArGrGrArUrArArArArUrATT 
SR504191B rGrArUrArUrUrGrArArGrArArArArUrUrArGrCrUrUrCrUGA 
SR504191C rCrUrUrArArArUrUrGrGrUrGrArArUrArArGrGrArCrArUGA 
 
2.3.6 Morphological assessments 
The cells grown in chamber slides were washed with 1 ml PBS and subsequently fixed by gently 
adding an equal amount of 4 % paraformaldehyde (PFA, Sigma-Aldrich, Germany), resulting in 2 
% PFA on the cells. After 2 min, this solution was discarded and replaced by 4 % PFA for 15 min 
at room temperature. The fixed cells were washed three times with PBS and permeabilized by 
500 μl PBS containing 0.1 % Triton X-100 (Sigma-Aldrich, Germany) for 5min. Unspecific binding 
sites were blocked by 30 min in PBS +0.1 % Triton and 10 % NGS. The actin filaments were stained 
by addition of 20 μl of 3.8 μM phalloidin tetramethylrhodamine B isothiocyanate (Sigma-Aldrich, 
Germany) directly on the cells without access to light for 20min. Phospho-MEF2A S408 specific 
antibody was diluted 1:500 in 5 % BSA/PBS-T and incubated on the cells overnight at 4 °C and 
gentle rocking. Nuclei were stained by addition of Gold anti-fade mounting medium containing 
4,6-diamidino-2-phenylindole (DAPI; Life Technologies, Germany). Cells were observed using the 
confocal microscope Leica SP8. Images were taken from four random fields per chamber. Neurite 
outgrowth was determined by manually tracing the length of the longest neurite per cell (using 
Fiji 1.51k) for all cells in a field that had an identifiable neurite and for which the entire neurite 
arbor could be visualized. Length of the neurite was measured from the edge of nucleus to the 
apical end of the projection. Four independent members of the team evaluated neurite length in 
a blinded manner. Hereby the MAX intensity Z-Projection was analyzed. DAPI images were used 
for nucleus size measurements and as MASK for mean intensity analysis of MEF2A S408 
phosphorylation exclusively in the nucleus. To assess the size of the cells, whole area 
measurements were performed by outlining the Phalloidin stained area. During all the 
measurements, grayscale images were processed.  To control for staining artifacts with Phalloidin 
or fixation artifacts we employed a second staining approach using the ZOE Fluorescence 
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microscope (Bio-Rad) and live cells in cell culture dishes. For nucleus staining, Hoechst 33342 
stain (Thermo Scientific, H1399) was added to the stimulation medium and incubated for 30 min 
at 37 °C. Hoechst staining is non-toxic and can therefore be used in living cells. After 20 min, 1× 
Plasmagreen membrane stain (Thermo Scientific, C37608) was added to the medium and co-
incubated for at least 10 min at 37 °C to label the cell plasma. This method circumvents any 
potential artifacts that could arise by the use of a specific Actin staining like Phalloidin. Cells were 
washed two times with 1× PBS before imaging of the blue (nuclei) and green (cell plasma) 
channel. All Pictures were analyzed using ImageJ Fiji software. 
2.3.7 Statistical analysis 
Data were pooled and analyzed using SigmaPlot 13. Parametric data was analyzed by t-test or 
one-way analysis of variance (ANOVA), followed by Holm Sidak post hoc test. Non-parametric 
data was analyzed by the Kruskal-Wallis ANOVA on ranks and the Tukey post hoc test, or in case 
of different group sizes, Dunn's post hoc test. Statistical differences were accepted at p < 0.05. 
For morphology analysis experiments with large n-numbers, analysis of effect size was 
performed. As indicator of effect size, either Cohen's f2-value where f2 < 0.02 is considered as 
small effect size, f2 = 0.15 is considered as median f2 > 0.35 as strong effect or eta squared (η2), 
where η2 < 0.039 is considered as small effect, η2 < 0.06–0.110 as intermediate, and η2 > 0.14 as 
strong effect, was calculated. Data are presented as means ± or + standard error of the mean 
(SEM), as indicated in the figure legend. 
2.4 Results 
2.4.1 OTR activation mediates OT-induced changes in neurite length and 
nucleus size 
Increasing concentrations (10 nM, 100 nM, and 1 μM) and treatment duration (0, 2, 4, 6, and 8 
h) of OT were tested with rat hypothalamic H32 cells, in order to reveal dose- and time-
dependent effects of OT treatment on neurite outgrowth (Figure 4A). VEH-treated cells elongate 
their neurites over a time course of 10 h significantly from about 37 μm up to 45 μm (# p < 0.05 
10 h vs 2 h). In contrast, OT treated H32 cells retracted their neurites from about 37 μm to about 
27 μm over time and in a dose-dependent manner. In detail, 100 nM OT significantly reduced 
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neurite length (* p < 0.05 vs VEH, intermediate effect f2 = 0.123) after 2 h, with further retraction 
of neurites until 10 h of treatment. 1 μM of OT induced a slower onset of neurite retraction 
(significant at 4 h), but with a more prominent effect size (* p < 0.05 vs VEH, strong effect f2 = 
0.477). After 8 and 10 h of cell stimulation, all treatment groups showed a reduced neurite length 
(* p < 0.05 vs VEH, median effect f2 = 0.267 after 8 h, very strong effect f2 = 0.77 after 10 h). As 
H32 cells also express the vasopressin receptor V1a, we tested whether the observed neurite 
retraction is mediated by the OTR, V1a, or a combination of both. Therefore, we incubated the 
cells with vasopressin or the specific OTR agonist TGOT. Similar to the OT-induced effect, 
vasopressin and TGOT (both 100 nM) significantly reduced neurite length over time (Figure 4B; * 
p < 0.05 vs VEH). However, vasopressin showed a slower onset of action compared to OT and 
TGOT, as after 2 h neurite length was not altered by vasopressin, but significantly reduced by OT 
and TGOT (100 nM; * p < 0.05 vs VEH, intermediate effect f2 = 0.123). Despite the slow onset of 
vasopressin action, after 4, 8, and 10 h, neurite length was significantly reduced in all treatment 
groups (* p < 0.05 vs VEH). To further dissect the morphological changes described in Figure 4A 
and B, we analyzed the OT-induced neurite length, whole cell size, and nucleus size separately in 
presence or absence of an OTR antagonist. We found that the OT-induced neurite retraction can 
be blocked by the specific OTR antagonist des-Gly-NH2d(CH2)5[Tyr(Me)2Thr4]-OVT (* p < 0.05 vs 
VEH, # p < 0.05 vs OT, Figure 4E), indicating that OT acts via the OTR on cellular morphology. 
There was no effect of OT or the antagonist on the whole cell size (i.e. total area covered by 
perikaryon, nucleus, and neurites), indicating a specific effect on cell shape, rather than growth 
or shrinking (Figure 4F). However, the size of the area stained by DAPI (a rough indicator of 
transcriptional activity) was increased by OT, and this effect was not reversed by the OTR 
antagonist, indicating OTR-independent transcriptional activity (* p < 0.05 vs VEH, Figure 4G).  
Oxytocin alters the morphology of hypothalamic neurons 
- 19 - 
 
 
Figure 4. Effects of an OTR activation on neuronal morphology in rat hypothalamic H32 cells. (A) Mean neurite length 
of H32 cells determined at increasing OT concentrations from 0 h to 10 h. Neurite length decreases significantly from 
about 37 μm to about 27 μm over the course of 10 h of OT stimulation at 10 nM, 100 nM, or 1 μM; while VEH treated 
cells show increased neurite length after 10 h. * p < 0.05 vs VEH, #<0.05 vs previous timepoint. n = 314–628 cells. 
(B) Incubation of H32 cells with OT (100 nM), the OTR agonist TGOT (100 nM), or vasopressin (VP, 100 nM) over 10 
h leads to neurite retraction to a similar extent as seen in Figure 4A. n = 314–801 cells. (C) and (D) Representative 
pictures of non-treated H32 cells (C) and 100 nM OT-treated cells (D) for 4 h; cytoplasm, including neurites stained 
with CellMask plasma membrane stain (green) and nuclei stained blue with Hoechst 33342. Scale bar represents 100 
μm. (E) Neurite retraction of OT-treated H32 cells after 12 h of stimulation is reversed when incubated with the OT 
antagonist (OTA, des-Gly-NH2d(CH2)5[Tyr(Me)2Thr4]-OVT). The OTA alone has no effect on neurite length. * p < 0.05 
vs VEH, # < 0.05 vs OT-treated cells. (F) Whole cell size analyzed as mean of total area covered by individual cells (i.e. 
perikaryon, nucleus, and neurites). No effect of the treatment was determined. (G) Overnight treatment of H32 cells 
with 100 nM OT led to an increase of area stained by DAPI, indicative of the size of the nuclear compartment. The 
OTA reduced the increase of size of the nuclear compartment, without reaching basal levels. * p < 0.05 vs VEH. Data 
represents mean + SEM. n = 21–74 cells. 
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2.4.2 OT leads to a MAPK-dependent neurite retraction as well as increased cell 
viability, whereas vasopressin affects neurite length MAPK-independently 
In order to exclude technical artifacts of the CellMask staining protocol in living cells used in 
Figure 4, we successfully reproduced our initial finding of reduced neurite outgrowth by 100 nM 
OT treatment with a different staining protocol (fixated cells, actin filament staining with 
Phalloidin, and evaluation by confocal microscopy; Figure 5A, * p < 0.05, intermediate effect size 
η2 = 0.078). When pretreated with the MAPK inhibitor U0126 (10 μM) the effect of OT was 
blocked, suggesting a central role for the MAPK pathway in the OT-induced neurite retraction. 
Surprisingly, vasopressin also reduced neurite length, in presence or absence of U0126, indicating 
that neurite retraction by vasopressin is coupled to a separate, yet unknown pathway (* p < 0.05, 
intermediate effect size η2 = 0.078). However, a partial role of the OTR cannot be excluded, as 
vasopressin also binds the OTR with a comparable affinity (Manning et al., 2008). Overnight 
stimulation with the specific agonist TGOT did not result in significantly altered neurite length. 
As stimulation with TGOT for only 10 h decreased neurite length from 37 to 27 μm (Figure 4A), 
but after prolonged (overnight) OT stimulation morphology changes were reversed to basal, we 
hypothesize that the exclusive OTR response is short lived (max. 10 h) and requires the additional 
activation of the vasopressin receptor for a prolonged response. Consequently, Figure 4B and 5A 
indicate that, in contrast to the fast and short-lived OTR response, vasopressin has a slow onset 
of action on neurite retraction (no effect after 2 h, Figure 4B), but bigger effect after prolonged 
incubation (overnight, mean difference of the neurite length compared to the non-treated group: 
−8.98 μm for VP vs. −6.47 μm for OT, Figure 5A). Morphological assessments of neuronal cells 
should only be conducted under optimal culturing conditions, which led us to control our 
experimental setup for general cell viability (i.e. ability to reduce resazurin to resafurin) and cell 
proliferation (cell number). Both OT and vasopressin treatment increased cellular viability, as 
reflected by the increased amount of resafurin, suggesting a pro-active, and not apoptosis-
induced retraction of neurites. In addition, the OT-induced increase in cell viability is MAPK-
dependent, as pretreatment with U0126 blocked this effect (Figure 5B). Comparable to the 
MAPK-independent effect of vasopressin on neurite length (Figure 5A), cell viability of 
vasopressin-treated cells was increased, independent of MAPK inhibition, thereby again 
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excluding a role for the MAPK pathway in vasopressin-mediated effects. Moreover, in support of 
our hypothesis of a short-lived nature of the OTR response, neurite outgrowth (Figure 5A) and 
cell viability (Figure 5B) returned to baseline after an overnight incubation with TGOT. This finding 
was further supported by the lack of effect of TGOT on cell proliferation, in contrast to the dose 
dependent increase of proliferation by 100 nM or 1 μM OT overnight treatment (* p < 0.05, Figure 
5C). 
 
 
Figure 5. Effects of OTR activation on cell morphology, viability, and proliferation in rat hypothalamic H32 cells. (A) 
Effect of overnight incubation with 100 nM OT, vasopressin (VP), or TGOT, in presence or absence of the MEK1/2 
inhibitor U0126 (10 μM) on neurite length in H32 cells. OT reduces neurite length significantly and in dependence of 
the MAPK pathway, whereas VP leads to neurite retraction independently of the MAPK pathway. TGOT has no 
significant effect. n = 65–200. (B) The effect on neurite length is accompanied by increased cell viability, which is 
blocked by U0126 in the OT-, but not in the vasopressin-treated cells. n = 18–48 wells. (C) Dose dependent increasing 
proliferation of cells treated with 10 nM (no effect), 100 nM (+∼100 cells) and 1 μM OT (+∼120 cells), but lack of 
effect with 100 nM VP and TGOT. n = 4–5 pictures. * p < 0.05 vs respective VEH. Data represent mean + SEM. 
 
2.4.3 OT increases transcriptional activity of MEF2A 
As increased nucleus size is a rough indicator for open chromatin, i.e. increased transcriptional 
activity, we tested the activation status of the transcription factor MEF2A by assessing its 
phosphorylation at S408. At this residue, dephosphorylation leads to transcriptional disinhibition. 
Western Blot analysis revealed that incubation with 100 nM OT led to a reduced level of phospho-
MEF2A S408 in whole cell lysate in a MAPK-dependent manner, indicating increased 
transcriptional activity (Figure 6A). The observed changes were validated by 
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immunohistochemical stainings, which revealed reduced intensity of pMEF2A S408 staining in 
the nuclear compartment, while staining in the cytoplasm was virtually absent (Figure 6B and 
6C), indicating a dephosphorylation event in the nucleus and not translocation of pMEF2A S408 
to the cytoplasm. 
 
Figure 6. Effect of OT on phosphorylation 
of S408 and localization of MEF2A. (A) 
Relative MEF2A S408 phosphorylation 
analyzed by Western Blot in whole cell 
lysate after treatment with VEH, OT, in 
presence or absence of MAPK inhibitor 
U0126, with representative Blot picture 
below. Incubation of H32 cells with 100 
nM OT over 12 h led to a ∼ 50 % 
dephosphorylation of MEF2A at S408 
compared to VEH treated. This effect is 
mediated via the MAPK pathway as it is 
reversed to basal by U0126 (10 μM). 
U0126 treatment without OT had no 
effect on MEF2A phosphorylation. n = 8. 
(B) Intensity of IHC stained pMEF2A S408 
in the nucleus of H32 cells treated with 
VEH or 100 nM OT. * p < 0.05 vs VEH. n 
(VEH) = 22, n (OT) = 13. (C) Representative 
images of IHC staining for pMEF2A S408 in 
H32 cells. Images were sequentially recorded for chromatin (DAPI, blue, first column), F-actin (Phalloidin, red, second 
column), and anti-pMEF2A S408 (green, third column). Merged images are shown for each row in the fourth column. 
Labels left to the columns indicate the respective treatment for 12 h. Scale bar represents 20 μm. Data represent 
mean + SEM. 
2.4.4 OT-induced neurite retraction is reversed by MEF2A knock down 
To provide a causal link between the activation of MEF2A and the neurite retraction induced by 
OT, we specifically knocked down MEF2A in H32 cells by siRNA, and assessed the effects of OT 
on neurite length 72 h after transfection, a time point where the knock down was most effective. 
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MEF2A protein levels were highly effectively reduced by 85 % of the baseline level, and OT 
treatment did not affect this knock down (Figure 7A). Scrambled siRNA (scrRNA) served as 
transfection control and did not alter MEF2A protein levels significantly compared to non-
transfected cells. Neurite length in cells that were transfected with scrambled or siRNA averaged 
around 47 μm (as compared to ∼ 37 μm of non-transfected, 12 h cultured cells in Figure 4E), as 
a result of prolonged culturing protocol, necessitated by the preceding transfection procedure. 
Statistical analysis by one way ANOVA did not reveal a significant difference. However, separate 
statistical analysis by direct comparison of the control (-MEF2A siRNA/+OT) versus the MEF2A 
knock down (+MEF2A siRNA/+OT) groups confirmed the observed OT-induced reduction in 
neurite length whereas, in contrast, this effect was prevented by MEF2A knock down (Figure 7B). 
The lack of effect of OT on neurite length when MEF2A is knocked down reveals the central role 
of MEF2A in the regulation of cellular morphology by OT. 
 
Figure 7. Effect of MEF2A 
knockdown on neuronal 
morphology. (A) Relative MEF2A 
protein expression in whole cell 
lysate after treatment with 1 nM 
scrRNA or 1 nM MEF2A siRNA for 72 
h and overnight stimulation with 
100 nM OT. Total MEF2A protein is 
reduced after treatment with 
MEF2A siRNA compared to scrRNA-
treated cells, which served as 
control. Representative Blot below 
the graph. n = 6. (B) Changes in the 
neurite length of H32 cells treated 
with either scrRNA or MEF2A siRNA 
in presence or absence of 100 nM 
OT. n = 339–336 cells. * p < 0.05 vs 
scrRNA control. Data represent 
mean + SEM. (C) and (D) 
Representative pictures of H32 cells 
treated with scrRNA + OT (C) or 
siRNA + OT (D); cytoplasm, including 
neurites stained with CellMask 
plasma membrane stain (green) and 
nuclei stained blue with Hoechst 
33342. Scale bar represents 100 μm. 
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2.5 Discussion 
In this study, we provide evidence for the ability of OT to induce neurite retraction in 
hypothalamic neurons in vitro. Specifically, we show that OT stimulation of H32 cells reduced 
neurite outgrowth in a dose- and time-dependent manner, without changes in whole cell size 
and under conditions of optimal cell viability. TGOT-induced neurite retraction, and the blockade 
of the OT-effect by a specific OTR antagonist provide evidence for the central role of the OTR, 
while the activation of the V1a receptor contributes to this effect with a prolonged cellular 
response. The signaling cascade coupled to the OTR and being responsible for the neurite 
retraction is the MEK1/2-ERK1/2 MAPK cascade. In previous studies we could show that OT 
infused into the PVN activates the MEK1/2 – ERK1/2 cascade in male rats (Blume et al., 2008), 
and similar effects of endogenous OT were found during pregnancy and in lactation in female 
rats (Jurek et al., 2012). When OT is applied into the hypothalamic PVN, it reduces anxiety-like 
behavior in a MEK1/2-dependent manner (Jurek et al., 2012; Blume et al., 2008), indicating a 
behavioral relevance for this pathway. It remains to be elucidated, whether the OT-induced 
neurite retraction, which is also MEK1/2-dependent, underlies the decreased anxiety-like 
behavior in rats. 
In this study, we could also identify the transcription factor that lies downstream of the MAPK 
pathway, MEF2A. To our knowledge, there is only one preliminary report on a link between the 
OTR and MEF2, and that has been described to be the big MAP kinase ERK5 (also known as bmk1) 
in myometrial cells (Devost et al., 2008). Here, we reveal this link to be existent also in neuronal 
cells. In addition, the elusive functional relevance of this pathway could, at least in neurons, be 
pinned down to the regulation of neurite outgrowth. In the original publication, Devost and 
colleagues described the activation of MEF2 as ERK5-dependent using U0126 - a non-specific 
MEK1/2 inhibitor that also targets ERK5. Thus, the possibility of an OTR-ERK5-MEF2 pathway also 
exists in neurons. However, ERK5 expression in the brain decreases dramatically after the early 
embryonic phase (Liu et al., 2003), and we could not detect ERK5 phosphorylation in H32 cells by 
OT stimulation (own unpublished data). Therefore, we suppose that the blockade of MEK1/2 by 
U0126 is causal for the inhibited effect of OT on neurite outgrowth.  
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Interestingly, OT had no effect on the overall cell size (consisting of the area covered by 
perikaryon, nucleus, and neurite processes). This indicates that neurite retraction is a 
consequence of rearrangement of actin filaments rather than of cell shrinking or growing. As 
Phalloidin staining does not differentiate between axons and dendrites in our cell culture 
experiments but stains actin filaments, it remains to be addressed, whether dendrites or axons 
of OTR-expressing neurons in the brain are affected by the OT treatment. Specific staining 
techniques, such as immunostaining using MAP2 antibodies for dendrites, and Tau for axons are 
feasible methods to settle those open questions in vitro. However, assessing cellular morphology 
in vivo, especially in the PVN, is difficult to achieve since axons and dendrites are extremely 
intermingled and difficult to map in this region (own observation). In addition to changes in the 
cytoplasmic actin filaments, the area covered by nucleus staining was increased in OT treated 
cells. However, we used DAPI, a specific stain for chromatin only, but not the total area covered 
by the nuclear compartment, nor the nuclear membrane. As an increased area covered by 
chromatin is indicative of increased gene transcription activity, future studies need to reveal the 
nature of the target genes of MEF2. In this context it is worth-mentioning that there exist 
genome-wide data on MEF2 target genes in hippocampal neurons. This potential transcriptional 
program is also very likely to be activated by MEF2A in hypothalamic neurons (Flavell et al., 2008). 
Most of the target genes regulated by MEF2 are related to activity-dependent synapse 
development, and, if dysregulated, can contribute to the etiology of epilepsy or ASD (Flavell et 
al., 2008). This regulatory role of MEF2 in synapse development supports our findings of OT-
induced morphological changes, as those are the prerequisite to synapse formation and pruning. 
Disturbances in neuronal dendrite organization were associated with various 
neurodevelopmental disorders such as ASD (Kulkarni and Firestein, 2012). The robust effect of 
OT treatment on neurite retraction of H32 cells was supported by the finding that the specific 
OTR agonist TGOT also led to neurite retraction to a similar extent, indicating a specific OTR-
mediated effect. In line with that data, the OTR antagonist blocked the OT-induced neurite 
retraction. It is therefore rather surprising that vasopressin treatment of H32 cells also led to 
neurite retraction. Consequently, there are two possibilities: both receptor types work in 
conjunction to induce neurite retraction, or the effect of vasopressin was caused by vasopressin 
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binding to the OTR. H32 cells express only one type of vasopressin receptor, the V1a (own 
unpublished data). As there is no selective rat V1a agonist (that does not bind the OTR) available 
(Marir et al., 2013), we have to leave this research question to be answered by future studies, 
where knock out cell lines could be used to determine the exact roles of both receptors in neurite 
retraction. To exclude any morphological changes evoked by a reduced cellular viability, we 
conducted cell viability assays. We found that both OT and vasopressin rather increase the 
cellular viability to a similar extent, in line with the existing literature (Bakos et al., 2012; 
Jafarzadeh et al., 2014; Lestanova et al., 2017), which excludes neurite retraction due to the onset 
of apoptosis. However, the processes of increased cell viability and therefore increased 
proliferation might be causally linked to the retraction of neurites. Therefore, two different 
scenarios are possible: either increased cell proliferation causes neurite retraction, or 
proliferation and neurite retraction are two independent processes, as it has been described 
recently (Latchney et al., 2015). As both processes depend on MEF2A activity (Pon and Marra, 
2016), the functional differentiation still remains to be addressed. Interestingly, there is 
conflicting data described in literature on OT's effects on cellular morphology. Recently, one 
study showed that transient OT exposure in vitro leads to a reduced dendrite complexity and 
synapse density in hippocampal glutamatergic neurons (Ripamonti et al., 2017). Another study 
described OT as being effective in increasing gene and protein expression in human SH-SY5Y cells 
(Lestanova et al., 2016), and this increase is associated with increased cell proliferation and 
increased neurite outgrowth. Own expression analyses revealed that SH-SY5Y cells lack MEF2A 
expression and, therefore, might show a differential response to OT than our H32 cells, which do 
express MEF2A. Supporting this assumption of cell-specific MEF2A expression and functioning, a 
central role for MEF2 in neuronal remodeling has also been detected in hippocampal neurons, 
cerebellar granule neurons, and medium spiny neurons of the nucleus accumbens both in vitro 
and in vivo (Flavell et al., 2006; Barbosa et al., 2008; Pulipparacharuvil et al., 2008; Shalizi et al., 
2006). 
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2.6 Conclusion 
In summary, this study elucidates the signaling cascade underlying the OT-mediated neurite 
retraction in hypothalamic neurons. We could show that this effect is mediated mainly via the 
OTR, with potential contributions of the V1a receptor. Stimulation of the OTR leads to an 
activation of the MEK1/2-ERK1/2 MAPK pathway and transcription factor MEF2A. Blocking the 
MAPK pathway by the MEK1/2 inhibitor U0126, as well as siRNA-mediated knock down of MEF2A, 
inhibited the OT-induced neurite retraction. Taken together, these results indicate a central role 
of the OTR-MAPK-MEF2A-pathway in morphological alterations of hypothalamic neurons. 
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3 Myocyte enhancer factor 2A (MEF2A) defines oxytocin-induced 
morphological effects and regulates mitochondrial function in neurons 
3.1 Abstract 
The neuropeptide OT is a well-described modulator of socio-emotional traits, such as anxiety, 
stress, social behavior, and pair bonding. However, when dysregulated, it is associated with 
adverse psychiatric traits, such as various aspects of ASD. In this study, we identify the 
transcription factor MEF2A as the common link between OT and cellular changes symptomatic 
for ASD, encompassing neuronal morphology, connectivity, and mitochondrial function. We 
provide evidence for MEF2A as the decisive factor defining the cellular response to OT: while OT 
induces neurite retraction in MEF2A expressing neurons, OT causes neurite outgrowth in absence 
of MEF2A. A CRISPR-Cas-mediated knockout of MEF2A and retransfection of an active version or 
permanently inactive mutant, respectively, validated our findings. We also identified the 
phosphatase CaN as the main upstream regulator of OT-induced MEF2A signaling. Further, 
MEF2A signaling dampens mitochondrial functioning in neurons, as MEF2A knockout cells show 
increased maximal cellular respiration, spare respiratory capacity, and total cellular ATP. In 
summary, we reveal a central role for OT-induced MEF2A activity as major regulator of cellular 
morphology as well as neuronal connectivity and mitochondrial functioning, with broad 
implications for a potential treatment of disorders based on morphological alterations or 
mitochondrial dysfunction. 
3.2 Introduction 
OT is a neuropeptide profoundly implicated in the regulation of various socio-emotional 
behaviors and physiological responses (Jurek and Neumann, 2018; Gimpl and Fahrenholz, 2001). 
Dysregulated plasma or salivary levels of OT have been associated with symptoms of ASD (Alaerts 
et al., 2019; Parker et al., 2014), depression (Yuen et al., 2014), and anxiety (Carson et al., 2015), 
and its intranasal application has been described to relieve some of those symptoms (Meyer-
Lindenberg et al., 2011). In particular, the pro-social effects of OT, as described by multiple 
groups (Lukas et al., 2011; Chen et al., 2011a; Chen et al., 2011b; Choe et al., 2015; Clipperton-
Allen et al., 2012), promise to relieve core deficits in social behavior in ASD patients. As a 
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multifactorial disorder, ASD has been associated with neuronal, morphological and mitochondrial 
dysfunctions (Maes et al., 2019; Falougy et al., 2019; Garcia-Cabezas et al., 2018; Young et al., 
2016; Bringas et al., 2013). One common factor between ASD, its underlying disturbed cellular 
functions and the oxytocinergic system, is the transcription factor MEF2. In this study, we provide 
evidence for the role of MEF2 as the central node in the regulation of those conditions. One major 
parameter in ASD patients is an alteration of the neuronal connectivity. Autistic patients show 
hyperconnectivity between amygdala and hippocampus, which is negatively correlated with 
peripheral OT levels, and can even be further decreased by intranasal application of OT (Alaerts 
et al., 2019). Although neuronal cell types differ between brain regions, i.e., hypothalamus and 
amygdala, the underlying molecular mechanism that connects OT receptor-coupled signaling 
with neuronal morphology seems to be identical in various cell types ((Jurek and Neumann, 2018) 
and references therein). In particular, transcriptomic responses to OT are similar in hypothalamic 
as well as amygdalar neurons (Jurek et al., 2015). Furthermore, neurons generated from iPSCs of 
ASD patients have more complex and longer neurites, causing increased synapse number and a 
state of hyperconnectivity (Zaslavsky et al., 2019; Tang et al., 2014). MEF2 is one factor that is 
responsible for the regulation of excitatory synapse number (Flavell et al., 2006; Shalizi et al., 
2006; Morrow et al., 2008), and we have recently provided evidence for its activation by OT 
receptor-coupled signaling pathways (Meyer et al., 2018). The activation of Gq protein-coupled 
OT receptors leads to an increase in intracellular Ca2+ from either intracellular stores (Sanborn, 
2007), through cation channels such as TrpV2/4 (van den Burg et al., 2015; Ying et al., 2015) or 
L-type voltage-gated Ca2+ channels (Zatkova et al., 2018). Upon OT-induced Ca2+ influx, the 
phosphatase CaN (or protein phosphatase 2B; PP2B) is activated by binding calmodulin (Pont et 
al., 2012). On the one hand, active CaN acts as a direct phosphatase of cytoskeletal proteins and 
influences the stability and interaction of microtubule and actin filaments (Descazeaud et al., 
2012; Xiong et al., 2018; Lautermilch and Spitzer, 2000). On the other hand, it dephosphorylates 
MEF2A at position S408 (Flavell et al., 2006; Shalizi et al., 2006), leading to a genomic response 
that consequentially impacts cellular morphology indirectly via transcriptional control of 
regulators of the cytoskeleton. Such regulators have recently been identified and linked to OT 
signaling by Bakos and colleagues, who found increased expression of the actin-binding proteins 
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drebrin, the intermediate filament vimentin, or the scaffolding protein SHANK3, under the 
influence of OT. This caused neurite outgrowth in human SH-SY5Y neuroblastoma or U-87MG 
glioblastoma cells (Zatkova et al., 2018; Lestanova et al., 2016; Bakos et al., 2018). As a 
consequence of neurite outgrowth, altered connectivity is observable due to increased synapse 
formation, which is under the OT-induced control of synaptic adhesion molecules such as 
neuroligin 3 or neurexin 2 (Zatkova et al., 2019). Since OT is produced in the hypothalamus and 
we have found profound anxiolytic and anti-stress effects of OT infused into the hypothalamic 
paraventricular nucleus (Jurek et al., 2015; Blume et al., 2008; Jurek et al., 2012; Martinetz et al., 
2019), we aimed to determine the intracellular effects of OT in a hypothalamic cell line, as 
opposed to neuroblastoma or glioblastoma cell types. As a cellular model of oxytocinergic effects, 
we have characterized the rat hypothalamic neuronal cell line H32, which expresses MEF2A 
endogenously, and retract their neurites upon OT stimulation, caused by MEF2A activation 
(Meyer et al., 2018). Neurite retraction was blocked by siRNA-mediated knockdown of MEF2A, 
or pharmacological blockade of the OT receptor-induced activation of the MAPK pathway by 
U0126. The observed neurite retraction was seemingly in contrast to the above-mentioned 
studies showing OT-induced neurite outgrowth in SH-SY5Y or U-87MG cells, but these are not 
hypothalamic neurons and might therefore react differently. In support of this hypothesis, we 
characterized the transcriptome of SH-SY5Y cells and found absent MEF2A expression. This 
phenotypical contrast led us to create a MEF2A knockout cell line, derived from our MEF2A-
positive H32 cells (H32∆MEF2A), using CRISPR-Cas9. In addition, we characterized another 
hypothalamic cell line (mHypoE-N11), which does not express endogenous MEF2A, and used 
those cells to overexpress MEF2A by plasmid transfection. By site-directed mutagenesis, we 
substituted the serine at position 408 to aspartate, creating a permanent phospho-mimetic 
MEF2A mutant. This mutant, transfected into H32∆MEF2A cells, served as control for phospho-
site-specific effects of MEF2A, since MEF2A can be phosphorylated at three different residues, 
namely S408, Thr312, and Thr319, with opposing outcomes for gene transcription (Potthoff and 
Olson, 2007). Those three hypothalamic cell lines serve as internal controls in our experimental 
setup and aid in determining the morphological outcome of OT stimulation in hypothalamic cells 
in the presence or absence of MEF2A. Cytoskeletal rearrangements are energy-consuming 
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events, requiring proper functioning of mitochondria. The organelles produce adenosine 
triphosphate (ATP) and provide energy for several cellular processes in neurons including action 
potential generation, but also morphological changes such as neurite growth. Many 
neurodegenerative diseases with a loss of neuronal function and morphology show 
accompanying mitochondrial malfunctions (Mattson et al., 2008). Intriguingly, MEF2 regulates 
transcription of the mitochondrial NADH dehydrogenase 6 gene, which is essential for the 
function of the oxidative phosphorylation system (Naya et al., 2002; She et al., 2011), which 
ultimately regulates the production of ATP. In line with that, a significant proportion of ASD 
patients suffer from abnormal ATP production (Rossignol and Frye, 2014; Siddiqui et al., 2016), 
suggesting a central role for the OT-regulated transcription factor MEF2 in energy balance, 
structural plasticity, and ASD (also see (Shalizi et al., 2006; Meyer et al., 2018; Fiore et al., 2009; 
Pfeiffer et al., 2010; Brusco and Haas, 2015)). To test this hypothesis, we manipulated MEF2A 
activity in hypothalamic neurons and monitored morphological alterations and mitochondrial 
functionality. 
3.3 Material and methods 
3.3.1 Cell culture 
Rat hypothalamic H32 cells ([48] kindly provided by Prof. Greti Aguilera (NICHD, Bethesda, MD)) 
and mouse hypothalamic mHypoE-N11 cells (kindly provided by Prof. Eugen Kerkhoff, University 
of Regensburg) were cultured in DMEM (#D8437, Sigma Aldrich, Darmstadt, Germany), 
supplemented with 10 % heat-inactivated Gold fetal bovine serum (#FBS-HI-11A, Capricorn, 
Germany), and Penicillin/Streptomycin (#P4333, Sigma Aldrich, Darmstadt, Germany) at 37 °C 
and 5 % CO2 until 80 % confluency. Passaging was performed at least once a week by gentle 
trypsinization. Cells were counted and seeded at 3 × 106 cells/75 cm2 density. Cell counts were 
recorded and compared between wildtype and knockout cell lines to extrapolate proliferation 
rates. 
3.3.2 CRISPR-Cas9 mediated knockout of MEF2A 
The rat hypothalamic neuronal cell line H32 served as host to create an MEF2A knockout cell 
line (H32∆MEF2A), using the Alt-R® CRISPR-Cas9 system (IDT, Coralville, USA). RNP complexes 
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were composed of the functional gRNA duplex, containing the sequence-specific crRNA 
(sequence ID: Rn.Cas9.MEF2A.1.AC; 50-A*C*A*G*A*C*C*T*C*A*C*G*G*T*A*C*C*A*A*A-30) 
and the ATTO 550-labeled tracrRNA in nuclease-free duplex buffer, and the S. p. Cas9 Nuclease 
3NLS. The complexes were transfected by cationic lipid delivery using LipofectamineTM RNAiMAX 
Transfection Reagent (Invitrogen, Carlsbad, CA, USA) and Opti-MEM (Gibco, Waltham, MA). 
Transfected single-cells were obtained 2 h after transfection by cell sorting and recultured for 
several weeks. The genotype was assessed by means of Western blotting. 
3.3.3 Transfection of H32 and mHypoE-N11 Cells with MEF2A overexpression 
plasmids 
For morphological analyses, cells were transfected with plasmids (VectorBuilder, Neu-Isenburg, 
Germany) by electroporation using the manufacturer’s nucleofector (Thermo Scientific, 
Waltham, MA) protocol. In total, 1 million cells were transfected with 0.5 µg of rat/mouse MEF2A 
plasmids. After a 48 h incubation, cells were further processed. The mouse hypothalamic cell line 
mHypoE-N11 was transfected with wildtype mouse MEF2A, resulting in mHypoE-N11MEF2A 
cells. H32∆MEF2A cells were transfected with either the wildtype variant of 
MEF2A(H32∆MEF2AMEF2A) or a phospho-mimetic MEF2A mutant (H32∆MEF2AMEF2A[S408D]). 
3.3.4 Cell stimulations 
Cells were stimulated overnight with 10, 100 or 250 nM of OT (Bachem, Bubendorf, Switzerland) 
in cell culture dishes or chamber slides (BD Falcon, Germany). For the inhibition of CaN, CaN 
autoinhibitory peptide (#1891, Tocris, Wiesbaden, Germany) was used at a concentration of 10 
µM (Perrino et al., 1995). Cells were pretreated with the inhibitor for 30 min and stimulated with 
the corresponding treatment. Non-treated cells are indicated as vehicle (VEH). 
3.3.5 Protein isolation 
For the extraction of proteins from OT- or vehicle (H2O)-stimulated 80 % confluent H32 cells, the 
stimulation medium was removed, and cells were washed with 5 mL ice-cold PBS (#D8537, Sigma 
Aldrich). Cells were scraped in 1 mL ice-cold PBS using a cell scraper (#83.1830, Sarstedt, 
Nümbrecht, Germany), collected in 15 mL tubes in PBS, centrifuged at 300 g and 4 °C for 5 min, 
and then the resulting cell pellet was resuspended in 30–100 µL RIPA lysis buffer (R0278, Sigma 
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Aldrich, Darmstadt, Germany) supplemented with HALT inhibitor and EDTA (78444, Thermo 
Fisher, Waltham, MA) to obtain whole cell lysates. 
3.3.6 Western blotting 
Western blotting was conducted as previously described in (Meyer et al., 2018). Briefly, 15 or 20 
µg of whole cell extract were loaded and separated in a 12 % Mini PROTEAN or Criterion TGX 
Stainfree gel (Bio-Rad, Feldkirchen, Germany), respectively. Semi-dry blotting of separated 
proteins to nitrocellulose membranes was conducted using the FAST Blotter by Bio-Rad. Uniform 
total protein loading was controlled for by the Stainfree total protein method by Bio-Rad. Specific 
antibodies for MEF2A, pMEFA S408, pMEK 1/2 and integrin ß1 (Table 2) indicated activity and 
expression levels of the protein of interest. 
Table 2. Summary of antibodies used in this study with corresponding dilution and host. 
Antibody Company and CAT 
Number 
Dilution and 
Diluent 
Secondary Antibody 
MEF2A total Acris AP06372PU-N 1:2000 in 5 % MP HRP-coupled anti-rabbit 
pMEF2A S408 CusAb PA000728 1:5000 in 5 % BSA HRP-coupled anti-rabbit 
pMEK1/2 4199 Cell Signaling 9154 1:5000 in 5 % BSA HRP-coupled anti-rabbit 
Integrin ß1 (N-20) Santa Cruz sc-6622 1:1000 in 5 % BSA HRP-coupled anti-goat 
 
3.3.7 Immunofluorescence 
mHypoE-N11 cells and mHypoE-N11MEF2A, as well as H32∆MEF2A and H32∆MEF2AMEF2A cell lines, 
were seeded on chamber slides (BD-Falcon, #08-774-25) at 6 × 104 cells per chamber and cultured 
overnight in growth medium at 37 °C/5 % CO2. Next, the growth medium was removed, and cells 
were briefly rinsed with warm PBS. The PBS was removed and replaced with 500 µL ice-cold 3 % 
glyoxal solution (+20 % EtOH, Acetic acid, pH = 4–5) for 20 min. After washing the cells twice with 
PBS-T (0.5 % tween), unspecific binding sites were blocked (PBS+0.5 % TritonX, 1 % glycine, 10 % 
BSA, 1 % normal goat serum) for 30 min, and antibody incubated overnight at the corresponding 
dilution. After intense washing with PBS-T, secondary antibody (CF488A highly cross-adsorbed 
#20123 BioTrend, Köln, Germany) was incubated at 1:500 in PBS for 30 min. After washing, cells 
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were incubated with Phalloidin-iFluor 594 Reagent (abcam ab176757), mounted with ProLong 
Glass-Antifade mounting medium with DAPI (Thermo Scientific, #P36982) and covered by cover 
slips (Thor Labs, refraction index 1,5; #CG15KH). Images were taken on a Zeiss AiryDisc Confocal 
microscope with a 63 × objective with identical laser and gain intensities to guarantee 
comparability between images. 
3.3.8 Morphological characterization 
For nucleus staining, Hoechst 33342 stain (H1399, Thermo Scientific, Waltham, MA) was added 
to the stimulation medium in the 6-well plates where cells were stimulated, and incubated for 
30 min at 37 °C. The cells grown in cell culture dishes were washed with 1 mL PBS and 
subsequently fixed by gently adding 3 % glyoxal solution for 20 min (3 % glyoxal in H2O, #128465, 
(Sigma Aldrich, Darmstadt, Germany), supplemented with 20 % EtOH and acetic acid to acquire 
pH = 5). All pictures were taken using the ZOE Fluorescence microscope (Bio-Rad, Feldkirchen, 
Germany). Neurite outgrowth was determined by manually tracing the length of the longest 
neurite per cell (using ImageJ Fiji version 1,52r software, NIH, USA) for all cells in a field that had 
an identifiable neurite and for which the entire neurite arbor could be visualized. Length of the 
neurite was measured from the edge of nucleus to the apical end of the projection. Only neurites 
that did not contact other cells were evaluated. At least two members of the team independently 
evaluated neurite length in a blinded manner. 
3.3.9 Cell viability assay 
Cellular viability was tested using the PrestoBlue Cell Viability Assay (A13261, Invitrogen, 
Carlsbad, CA) according to the manufacturer’s protocol and as described in (Meyer et al., 2018). 
Briefly, 10 × 103 cells per well were seeded the day before the test in a 96-well plate in growth 
medium. The volume of the treatment and medium for the stimulation was calculated to a total 
of 90 µL per well. In total, 10 µL of PrestoBlue Reagent was added directly to the cells and 
incubated for 30 min before reading the fluorescence intensity with a FluoStar Plate reader (BMG 
Labtech, Ortenberg, Germany). 
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3.3.10 Mitochondrial respiration analysis 
The oxygen consumption rate (OCR) of intact H32 and H32∆MEF2A cells was measured with the 
Agilent Seahorse XF Cell Mito Stress Test Kit (Agilent Technologies, Waldbronn, Germany) 
according to the manufacturer’s protocol. The live cell assay monitors OCR in real time and 
assesses the key parameters of mitochondrial function. Mitochondrial stress compounds used 
for this assay are oligomycin (1 µM), carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone 
(FCCP; 2 µM), and rotenone/antimycin A (1 µM). On the day before the measurement, 20 × 103 
cells were seeded in matrigel-coated XFp 8-well miniplates (Agilent Technologies, Waldbronn, 
Germany) at 37 °C, humidified air and 5 % CO2. Cartridges were prepared according to the 
provided protocol. The obtained values were normalized to the cell number present in the region 
of interest, reflecting the field of measurement by ImageJ. Data was analyzed using the WAVE 
software (Agilent Technologies, CA, USA) according to the manufacturer’s protocol. 
3.3.11 CellTiter-Glo 2.0 assay 
The CellTiter-Glo 2.0 assay (Promega) was conducted to measure cellular ATP content under 
basal/non-stimulated conditions in H32 and H32DMEF2A cells, according to the manufacturer’s 
protocol. Briefly, 10 × 103 cells per well were seeded the day before in a Nunclon Delta Surface 
96-well plate (Thermo Scientific, #136101). On the next day, an ATP standard curve was 
generated, and an equal volume of Cell Titer Reagent 2.0 was added to the culture medium 
present in each well. After a 12 min incubation, luminescence intensity was recorded with the 
GloMax Luminometer (Promega, Waldorf, Germany). The assay was repeated three times. 
3.3.12 Statistical analysis 
Statistical analyses were performed using Sigma Plot (version 13.0, Systat Software, Erkrath, 
Germany). Parametric data was analyzed by t-test or one-way ANOVA followed by the Holm–
Sidak post hoc test. Non-parametric data was analyzed by the Mann–Whitney Rank Sum test or 
Kruskal–Wallis ANOVA on ranks and the Tukey post hoc test. Statistical significance was accepted 
at p < 0.05. In morphological experiments, n represents the number of cells. In Western blotting, 
n represents the number of cell lysates. In the ATP and cell viability assays, n is number of wells. 
Parametric data is presented as the mean + standard deviation (SD). Non-parametric data is 
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represented in box plots as the minimum, first quartile, median, third quartile, and maximum. 
Details on statistics have been summarized in the Supplementary Materials. 
3.4 Results 
In order to study the impact of MEF2A in OT-induced effects on cellular morphology, we used cell 
lines that lacked, endogenously expressed, or were transfected with MEF2A. The mother cell line 
as well as all genetically altered daughter lines express the OT receptor, as validated by RT-qPCR. 
The hypothalamic rat cell line H32 was subjected to CRISPR-Cas-mediated knockout of MEF2A 
(H32∆MEF2A), and retransfected with either wildtype rat MEF2A (H32∆MEF2AMEF2A) or the 
mutant version H32∆MEF2AMEF2A[S408D], in which site-directed mutagenesis at S408D mimicked a 
permanently phosphorylated, and therefore transcriptionally inactive transcription factor. The 
mouse hypothalamic cell line mHypoE-N11 lacked MEF2A expression with levels below the 
detection limit of a qPCR. Transfection of those cells with a plasmid encoding for mouse MEF2A 
resulted in exogenous overexpression of MEF2A, as verified with immunofluorescence. The cell 
lines created and their MEF2A expression profile are summarized in Table 3. 
 
Table 3. Summary of cell lines used and created in this study. MEF2A protein levels have been assessed by means of 
Western blotting (Figure A3). mHypoE-N11 are derived from mouse hypothalamus neurons and lack endogenous 
MEF2A expression. Plasmid transfection caused MEF2A overexpression in those cells (mHypoE-N11MEF2A). H32 cells 
are immortalized neurons derived from a rat hypothalamus (Mugele et al., 1993) and show moderate endogenous 
expression of MEF2A (wildtype). CRISPR-Cas directed knock out of MEF2A produced H32∆MEF2A cells, 
retransfection of intact MEF2A into H32∆MEF2A cells rescued MEF2A expression (H32∆MEF2AMEF2A). 
Cell line mHypoE-N11 
(Mouse) 
H32 (Rat) 
Manipulation Wild-
type 
mHypoE-
N11MEF2A 
Wild-
type 
H32∆MEF2A H32∆MEF2AMEF2A H32∆MEF2AMEF2A[S408D] 
(inactive) 
Level of 
MEF2A 
- ++ + - ++ ++ 
 
Treatment of mouse hypothalamic MEF2A-deficient mHypoE-N11 cells (see Table 3), with 
increasing concentrations (10, 100 and 250 nM) of OT overnight, led to a dose-dependent 
increase in neurite length, which reached significance in the 100 and 250 nM treatment group, 
but not in the 10 nM group (Figure 8A). Statistical analyses for all figures are summarized in the 
Supplementary Materials, including details on p values and effect sizes. Overexpressing MEF2A 
in mHypoE-N11 cells by plasmid transfection with subsequent OT stimulation 48 h later revealed 
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a significant OT-induced retraction of neurites after 12 h in all doses tested (Figure 8B). Successful 
overexpression of MEF2A was controlled by immunostaining with an MEF2A-specific antibody 
(Figure 8C). As expected, we found mainly nuclear location of MEF2A, with partial cytosolic 
location, representing a normal localization of the transcription factor (Potthoff and Olson, 2007). 
Neither of the effects on neurite length was caused by altered cell viability. We found no decrease 
in cellular viability in H32 or H32∆MEF2A cells, and no increased cell viability in mHypoE-N11 cells 
under the influence of OT (Figure A2). This suggests that the OT-induced morphological effects 
are primarily alterations of the cytoskeleton, and not mere side effects of an apoptotic or 
otherwise constricted cell. The OT receptor specificity of the morphological effect has been 
addressed by the use of a specific OT receptor antagonist (des-Gly-NH2d(CH2)5[Tyr(Me)2Thr4]-
OVT) and agonist (Thr4 Gly7-OT, TGOT) in a previous publication (Meyer et al., 2018). 
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Figure 8. Effects of oxytocin (OT) on neuronal morphology in the mouse hypothalamic cell line mHypoE-N11. (A) 
Median neurite length increases significantly in wildtype mHypoE-N11 cells treated overnight with 100 or 250 nM 
OT. n = 100 cells per treatment; * p < 0.012 vs. VEH. (B) Treatment with 10, 100 and 250 nM of OT induces a significant 
neurite retraction in MEF2A overexpressing mHypoE-N11 cells. n = 100 cells per treatment; * p < 0.003 vs. VEH. (C) 
Representative images of immunofluorescence labelling for MEF2A. Images were sequentially recorded for F-actin 
(Phalloidin, red, first column), chromatin (DAPI, blue, second column), and MEF2A (green, third column). Merged 
images are shown for each row in the fourth column. Labels left to the columns indicate the respective cell type 
(wildtype vs. transfected). 
 
Having established the ‘gain-of-function-MEF2A’ model with the mHypoE-N11 cells, we 
determine whether a ‘loss-of-MEF2A-function’ model would reverse the oxytocinergic effect on 
cellular morphology. To obtain a permanent knockout of MEF2A, we made use of the CRISPR-
Cas9 technology to create a monoclonal knockout cell line derived from a single edited H32 clone. 
The efficiency of the knockout was validated by Western blotting. In contrast to OT-induced 
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neurite retraction in H32 wildtype cells, we found neurite elongation after stimulating 
H32∆MEF2A cells overnight with 100 and 250 nM OT (Figure 9A). Retransfection of those 
knockout cells with an intact wildtype MEF2A reversed the effect and initiated OT-induced 
neurite retraction (Figure 9B, light blue columns). However, when a phospho-mimetic, 
permanently inactive MEF2A [S408D] mutant was retransfected, neurite elongation was 
observed (Figure 9B, dark blue columns). This cellular response was comparable to the 
H32∆MEF2A cells (Figure 9A), revealing the S408 residue as the main phosphorylation site that 
orchestrates the OT effect on cellular morphology.  
 
Figure 9. Effects of oxytocin (OT) on neuronal morphology in the rat hypothalamic cell line H32. (A) Incubation of 
H32ΔMEF2A cells with 100 or 250 nM OT leads to a significant neurite elongation. n = 100 cells per treatment; * p < 
0.001 vs. VEH. (B) H32ΔMEF2A cells were retransfected with wild‐type MEF2A and a mutant version MEF2A[S408D], 
which mimics a permanently phosphorylated and therefore inactive MEF2A. The wild‐type MEF2A generated OT‐
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induced neurite retraction, whilst the mutant MEF2A lacked the ability to induce neurite retraction. Instead, the 
mutant response to OT resembled the MEF2A knockout cells. n = 100 cells per treatment; two‐way ANOVA; * p < 
0.031 treatments vs. VEH within the same group; # p < 0.002 groups (wildtype vs. mutant) within the same 
treatment. (C) Representative images of immunofluorescence labelling for MEF2A. Images were sequentially 
recorded for F‐actin (Phalloidin, red, first column), chromatin (DAPI, blue, second column), and MEF2A (green, third 
column). Merged images are shown for each row in the fourth column. Labels left to the columns indicate the 
respective cell type (knockout vs. transfected). 
 
We have shown in a previous publication (Meyer et al., 2018) that incubation of H32 cells with 
100 nM OT overnight led to a dephosphorylation and, therefore, activation, of MEF2A at S408, 
compared to VEH treated cells. This effect is indirectly mediated via the MAPK pathway, as it is 
reversed to basal by the MEK1/2 inhibitor U0126. This treatment does not alter the level of total 
MEF2A or MEK1/2 protein, as previously published by our group (Jurek et al., 2015; Meyer et al., 
2018; van den Burg et al., 2015; Jurek et al., 2012; Martinetz et al., 2019). 
In the present study, OT stimulation led to decreased MEF2A S408 phosphorylation, whereas 
addition of CaN inhibitor reversed the phosphorylation back to basal (Figure 10A). 
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Figure 10. Effect of oxytocin (OT) stimulation and calcineurin inhibition on phosphorylation of S408 of MEF2A and 
MEK1/2 as well as on the median neurite length in H32 cells. (A) Relative MEF2A S408 phosphorylation analyzed by 
Western blotting in whole cell lysate after treatment with VEH and OT, in the presence or absence of a CaN inhibitor 
(CaN‐INH), with representative blot below. Overnight incubation of H32 wild‐type cells with 100 nM OT led to a 
significant dephosphorylation of MEF2A at S408 compared to VEH treated cells (one‐way ANOVA, p = 0.056; 
independent t‐test VEH vs. OT, p = 0.006). This effect is dependent on CaN activity, as it is reversed to basal by a 
CaN‐INH. The inhibitor without OT had no effect on MEF2A phosphorylation. n = 6 per treatment. (B) Relative 
phosphorylation of MEK1/2 analyzed by Western blotting in whole cell lysate after treatment with VEH and OT, in 
the presence or absence of a CaN inhibitor, with representative blot picture below. Treatment of the cells with 100 
nM OT overnight led to a significant phosphorylation of MEK1/2 compared to VEH. Statistical analysis using one‐way 
ANOVA revealed no significant effect of the inhibitor treated cells, but a significant phosphorylation of MEK1/2 when 
cells were treated with OT and the CaN‐INH. n = 6 per treatment; * p < 0.05 vs. VEH. (C) In H32 cells, 100 nM of OT 
led to a significant retraction compared to VEH, while inhibition of CaN resulted in elongation of neurites overnight 
compared to VEH and OT. Combining the OT treatment with a CaN‐INH increased the neurite length significantly. n 
= 100 per treatment; * p < 0.001 vs. VEH‐treated cells; # p < 0.001 vs. OT-treated cells. (D) Incubation of mHypoE‐
N11 cells with 100 nM OT overnight led to an increased neurite length. Inhibition of CaN had no effect on the 
neuronal morphology, in line with the absent MEF2A expression in this cell line. n = 50 per treatment; * p < 0.05 vs. 
VEH-treated cells. 
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To test whether the observed CaN activation is related to the MAPK pathway, we assessed 
MEK1/2 phosphorylation after OT/CaN inhibitor treatment. Western blotting revealed MAPK 
pathway activation after OT treatment irrespective of the CaN inhibitor application, indicated by 
persistent MEK1/2 phosphorylation in the presence or absence of the CaN inhibitor. The inhibitor 
alone, despite a visual increase, had no significant effect on MEK1/2 phosphorylation (Figure 
10B). As expected, those effects translated into morphological changes, i.e., OT treatment (as 
shown in Figure 9B and (Meyer et al., 2018)) reduced neurite length from approximately 100 µm 
to approximately 75 µm, an effect that was blocked by the CaN inhibitor (Figure 10C). In line with 
this data, when CaN was blocked in mHypoE-N11 cells (which do not express MEF2A), OT retained 
its ability to increase neurite length (Figure 10D). This is in line with our hypothesis of the central 
role for the CaN-MEF2A pathway in OT-induced neurite retraction, but OT induces neurite 
outgrowth when MEF2A is absent. For examination of mitochondrial function, we analyzed intact 
H32 wild type and H32∆MEF2A cells with the Agilent Seahorse XF Cell Mito Stress Test Kit. After 
application of different stressors to the cells, the oxygen consumption rate was measured, which 
serves as an indicator for mitochondrial functioning (Figure 11A). H32∆MEF2A cells showed a 
significantly higher maximal respiration (Figure 11B) as well as spare respiratory capacity (Figure 
11C) compared to the MEF2A expressing H32 wildtype cells. This increased respiratory capacity 
in the H32∆MEF2A cells suggests an inhibitory role for MEF2A in mitochondrial functioning. As a 
direct consequence of this altered mitochondrial performance, basal cellular ATP content was 
significantly elevated in the H32∆MEF2A cells, when compared with the wildtype cells (Figure 
11D). This additional energy supply might contribute to the cytoskeletal rearrangements that 
cause neurite elongation observed under OT treatment. Neurite outgrowth serves to increase 
cell–cell contacts, which we hypothesized to simultaneously decrease cell–matrix contacts 
(Bikbaev et al., 2015; Chklovskii, 2004). As a representative indicator for decreased cell–matrix 
contacts, we assessed integrin ß1 receptor expression (Tomaselli et al., 1993), and found 
decreased protein expression in H32∆MEF2A cells compared to H32 wildtype cells (Figure 11E). 
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Figure 11. Effect of MEF2A knockout on mitochondrial function and neuronal connectivity. (A) The Agilent Seahorse 
XF Cell Mito Stress Test profile shows the oxygen consumption rate (OCR) in H32 wildtype (WT) and H32ΔMEF2A 
cells representing key parameters of mitochondrial function. (B) and (C) The OCR of both cell lines in the 
mitochondria stress test measured by Seahorse. H32ΔMEF2A cells show a significantly increased maximal respiration 
(* p = 0.004) and spare respiratory capacity (maximal vs. basal respiration, * p = 0.01) compared to H32 cells. n = 3 
test repetitions with 4 measurement replicates per group. (D) Cellular ATP content under basal conditions is 
significantly higher in H32ΔMEF2A than H32 WT cells. n = 24 per group; * p = 0.038. (E) Relative protein expression 
of integrin ß1 is significantly downregulated in H32ΔMEF2A cells compared to H32 WT cells. n (H32 WT) = 9, n 
(H32ΔMEF2A) = 10; * p < 0.001. 
 
3.5 Discussion 
In recent publications, OT has been considered as a potential treatment for the alleviation of 
adverse psychiatric traits, e.g., ASD‐related symptoms (Meyer-Lindenberg et al., 2011; 
Hurlemann, 2017; Kosfeld et al., 2005; Tost et al., 2010). The effects range from improving social 
skills in autistic children (Yatawara et al., 2016; Parker et al., 2017) to increased reciprocal trust 
in adult healthy probands (Kosfeld et al., 2005). However, the underlying molecular mechanism 
of the OT’s alleviating properties on the symptoms of ASD are not fully understood. Considering 
the cellular changes apparent in ASD patients, we focused on the main parameters of cellular 
morphology, mitochondrial function and neuronal connectivity in this study, providing evidence 
for MEF2A as central regulator of those processes (Figure 12). We have identified the 
transcription factor MEF2A as the defining parameter that shifts the OT-induced neuronal 
response from neurite outgrowth towards neurite retraction. Knockin or knockout of MEF2A 
produced dichotomic effects on neuronal morphology, but only in the presence of OT. When 
MEF2A is expressed, OT leads to transcriptional activation by dephosphorylation of the inhibitory 
site S408 of MEF2A, which promotes a switch from sumoylation to acetylation at Lys403 and 
subsequent inhibition of dendritic morphogenesis (Shalizi et al., 2007). In contrast, when we 
transfected MEF2A knockout cells with the transcriptionally inactive mutant 
(H32∆MEF2AMEF2A[S408D]), sumoylation at Lys403 was retained and dendritic morphogenesis 
occurred. Interestingly, the knockout of MEF2A and its phospho-mimetic mutation did not just 
inhibit neurite retraction, but actively induced neurite outgrowth under the influence of OT. This 
implies alternative OTR-coupled pathways, which are silenced or overruled when MEF2A is 
expressed and active. One potential pathway is the MAPK pathway, which is activated by the 
OTR, but not affected by the MEF2A knockout or inhibition of CaN. The MAPK pathway has been 
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associated with OT-induced anxiolysis, i.e., reduction of anxiety-like behavior in rats (Jurek et al., 
2015; van den Burg et al., 2015; Blume et al., 2008; Jurek et al., 2012; Martinetz et al., 2019) and 
targets transcription factors such as CREB and its cofactor CRTC3 (Jurek et al., 2015; Martinetz et 
al., 2019). The MAPK pathway is certainly one of the main effectors of OTR signaling (Jurek and 
Neumann, 2018); however, it might not be directly linked to MEF2A activation, mainly because 
the S408 residue requires dephosphorylation, not phosphorylation, for full transcriptional 
activation. Evidence from hippocampal neurons suggests that a Ca2+-dependent activation of 
MEF2A requires the CaN-dependent dephosphorylation of MEF2A (Flavell et al., 2006; Shalizi et 
al., 2006). Based on this data, we identified CaN as the central part of a signaling cascade coupled 
to the OTR and thereby influencing the morphological response. Inhibiting CaN diminished the 
OT-induced neurite retraction in the H32 cells, strongly suggesting CaN as the upstream 
phosphatase responsible for OT-induced MEF2A activation. Moreover, mHypoE-N11 cells that 
lack MEF2A as a target of CaN should not be affected by CaN inhibition. Indeed, blocking CaN 
activity did not interfere with OT-induced (MEF2A-independent) neurite elongation. Since the 
actions of CaN and the MAPK signaling pathway have been shown to be co-dependent (Zhou et 
al., 2001; Ichida and Finkel, 2001; Molkentin, 2004), we tested MEK1/2 activity under OT/CaN 
inhibition. In line with our hypothesis, OT-induced MEK1/2 phosphorylation was not affected by 
CaN inhibition, implying a direct activation of CaN by OTR-mediated Ca2+ influx through either 
TrpV2 channels (van den Burg et al., 2015), or release from intracellular stores ((Jurek and 
Neumann, 2018) and references therein). Furthermore, we provide evidence that a knockout of 
MEF2A has fundamental effects on mitochondrial functioning. While the basal respiration 
remains unaffected, the induced maximal respiration and spare respiratory capacity is 
significantly disinhibited compared to the wildtype cells. Next, we asked whether the increased 
respiratory capacity correlates with the ATP levels available for the cells. Interestingly, we found 
a significantly higher cellular ATP content under basal conditions in the H32∆MEF2A cells. 
Although basal respiration does not differ between the two cell types, the increased respiratory 
capacity of the H32∆MEF2A cells allows them to produce more ATP on demand, mainly due to 
the use of the more efficient aerobic pathway (see Energy Map, Figure A1). Whether the activity 
of MEF2A influences mitochondrial morphology or motility, and thereby respiratory 
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functionality, remains to be addressed by future studies. Whatever the effects on mitochondrial 
morphology and motility might be, the elevated ATP level present in the H32∆MEF2A cells is 
pivotal for the OT-induced neurite outgrowth. Changes in neurite outgrowth and plasticity are 
strongly intertwined processes implicated in the regulation of neuronal connectivity. Recent 
findings indicate that a state of neuronal hyperconnectivity may play an essential role in the 
etiology of ASD (Zaslavsky et al., 2019; Tang et al., 2014; Zhang et al., 2016). Many genes which 
have been associated with ASD and changes in neuronal connectivity belong to the integrin family 
(Lilja and Ivaska, 2018) and Ingenuity Pathway Analysis in myotube cells with MEF2 
downregulations revealed that integrin signaling is one of the few pathways targeted by all MEF2 
isoforms (Estrella et al., 2015). One member of this family is integrin β1, a cell surface receptor 
linking the actin cytoskeleton with the extracellular matrix (ECM), mediating cell adhesion and 
thereby information that influences cellular morphology (Werner and Werb, 2002). We showed 
that this receptor is significantly downregulated in the H32∆MEF2A cells. The effects of the 
MEF2A knockout on mitochondrial function and integrin signaling might not be causally 
connected. However, it has been suggested that alterations in mitochondrial function and 
integrin-mediated cell adhesion are functionally coupled processes (Werner and Werb, 2002). 
Crosstalk between cell adhesion and mitochondria is feasible, since it has been shown that 
mitochondria react to ECM composition changes, and in turn, modifications of the ECM can result 
as a consequence of mitochondrial functioning (de Cavanagh et al., 2009). Mitochondria play a 
role in the mechanosensing processes of cells since mechanical forces from the ECM are 
transmitted to mitochondria via focal adhesions (Bartolak-Suki et al., 2017). Therefore, it might 
be possible that the MEF2A knockout directly affects mitochondria by targeting the 
mitochondrial transcriptome or indirectly via mechanobiological changes transmitted by integrin 
receptors into the cells. Taken together, our results reveal a central role for MEF2A in the OT-
induced regulation of neuronal morphology, connectivity, and mitochondrial function. 
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Figure 12. Schematic summary of MEF2A activity in OT‐stimulated neurons. Neuronal MEF2A activity, induced by 
OT, reduces neurite length, decreases mitochondrial respiratory function, decreases ATP production, and increases 
integrin β1‐mediated cell–matrix contacts. The absence or inhibition of MEF2A induces neurite outgrowth, increased 
respiratory function, ATP production, and decreased cell–matrix connectivity. The schematic art pieces used in this 
figure were provided by Servier Medical art (http://servier.com/Powerpoint‐image‐bank). Servier Medical Art by 
Servier is licensed under a Creative Commons Attribution 3.0 Unported License. 
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3.6 Appendix 
 
Figure A1. Mitochondrial function in H32 wildtype and H32ΔMEF2A cells. n = 3 per group. 
 
Figure A2. (A) Cell viability in H32 vs. H32ΔMEF2A. n = 24 per group. (B) Cell viability in OT‐treated mHypoE‐N11 
cells. n = 22–24 per group.  
 
 
Figure A3. (A) and (B) Characterization of pMEF2A S408 and MEF2A total in mHypoE‐N11, H32ΔMEF2A and H32 cells. 
  
MEF2A defines oxytocin-induced morphological effects 
- 50 - 
 
 
 
Functional characterization of the oxytocin receptor variant A218T 
- 51 - 
 
 
4 Functional characterization of the oxytocin receptor variant A218T 
4.1 Abstract 
The OTR gene variant rs4686302, a non-synonymous SNP resulting in the OTR variant A218T, has 
been associated with core characteristics of ASD, social cognition deficits/attention disorders, 
and trait empathy in healthy persons. However, the underlying molecular mechanism that causes 
those traits is unknown. In this study, we provide evidence that the OTR variant A218T as well as 
an OTR gene duplication alters OT-induced intracellular signaling. In a functional in vitro study we 
created two monoclonal HEK293 cell lines, stably expressing either the OTR wildtype or the 
A218T variant. We performed whole genome and RNA sequencing with a subsequent gene 
ontology (GO) analysis and assessed several cellular parameters like the OTR protein stability, 
MAPK pathway activation and Ca2+ signaling. Upon stimulation with OT, RNA Sequencing analysis 
revealed 7823 differentially regulated genes, with 429 genes being associated with ASD. Our 
study provides new insights into the cellular effects of genetic variations affecting the OTR that 
have been associated with ASD, and their functional consequences on cellular processes as well 
as gene expression. 
4.2 Introduction 
The neuropeptide OT is involved in the regulation of diverse behaviors such as anxiety, reciprocal 
trust, aggression, or affective behavior (Jurek and Neumann, 2018). In addition, it has been 
suggested as biomarker and target for treatment of ASD since it has been shown to significantly 
improve the social impairments of autistic children (Parker et al., 2014; Parker et al., 2017). 
However, the therapeutic efficiency is highly variable between individuals (for meta review see 
(Bakermans-Kranenburg and van Ijzendoorn, 2014)). Numerous SNPs in the OTR have been 
mapped  and associated with a plethora of psychological traits in GWAS, however, most of the 
SNPs associated with a trait are intronic and/or synonymous mutations (Jurek and Neumann, 
2018). Since non-synonymous SNPs can affect the protein structure and thereby its function, they 
presumably generate the most significant impact on the phenotype. The SNP rs4686302 is 
located within the coding region of the third exon in the human OTR gene and is a non-
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synonymous SNP, leading to an amino acid exchange of alanine to threonine at the position 218 
(A218T) in the OTR protein. This position is located within the fifth transmembrane domain of 
the OTR protein, where it is prone to affect the recently described protein structure of the OTR 
(Waltenspühl Y. et al., 2020). These structural changes could affect the overall protein stability 
of the OTR, thereby changing the available receptor protein on the cell surface, representing a 
quantitative effect of the SNP. In addition, a qualitative effect of the SNP would encompass a 
change in protein structure that affects the positioning within or outside of caveolin-1-enriched 
lipid raft, and therefore the coupled intracellular signaling cascades (Cassoni et al., 2004). It has 
previously been shown that receptor positioning is a decisive factor for PKA or Ca2+-dependent 
signaling and has opposing outcomes for cell proliferation (Cassoni et al., 2004; Reversi et al., 
2006). Activation of the OTR and the subsequent coupling to one of its Gα proteins eventuates 
in Ca2+ release from intracellular stores in hypothalamic explants (Tobin et al., 2011) as well as 
Ca2+ influx from the extracellular space through TRPV2 channels in hypothalamic neuronal cell 
culture (van den Burg et al., 2015). Ca2+-dependent signaling transactivates the MAPK pathway, 
with ERK1/2 being the core factor for the behavioral anxiolytic and anti-stress effects of OT in 
vivo (Blume et al., 2008; Jurek et al., 2012; Jurek et al., 2015). The MAPK-ERK1/2 pathway signals 
to the nucleus to regulate gene transcription (Kyriakis and Avruch, 2012), which we monitored 
by RNA-Sequencing identifying OTR-regulated genes that are affected by the presence of OTR 
gene variants. 
On a behavioral level, rs4686302 has been linked to core symptoms of ASD and social cognition 
deficits (Francis et al., 2016; Kalyoncu et al., 2019). Besides these psychological conditions, 
rs4686302 has been associated with emotional empathy in non-clinical Chinese samples (Wu et 
al., 2012). To our knowledge, there is only one functional study showing that patients with the 
rs4686302 SNP display a higher sensitivity to OT stimulation, causing premature birth as well as 
a reduced cesarean section prevalence (Fueg et al., 2019). However, the mechanism underlying 
the increased sensitivity of the receptor in this setting has not been addressed yet. 
In order to better understand the underlying mechanisms that could explain the behavioral and 
physiological phenotypes, we aimed to characterize the functional relevance of the OTR A218T 
on a cellular level. Therefore, we transduced HEK293 cells with an N-terminal FLAG-tagged OTR 
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that comprises the reference sequence or the rs4686302 SNP. By means of FLAG-tag-directed 
fluorescence-activated cell sorting (FACS) we isolated single clones of OTR-positive cells to create 
a monoclonal wildtype and a SNP-containing cell line. To control for genomic effects and map the 
insertion site of the OTR gene we conducted whole genome sequencing. Assessment of OTR 
stability, Ca2+ influx, activation of receptor-coupled signaling cascades, and consequential 
alterations in gene transcription have been conducted in wildtype and SNP-containing cells. This 
experimental setup allows us to determine the functional relevance of the rs4686302 SNP, and 
assemble a comprehensive model of cellular effects that would ultimately affect complex 
behavioral traits associated with ASD. 
4.3 Material and methods 
4.3.1 Cell culture 
The HEK293 cell line was obtained from Prof. Dr. Eugen Kerkhoff from University Hospital 
Regensburg. Human HEK293 cells were cultured in DMEM (#D8437, Sigma Aldrich, Darmstadt, 
Germany), supplemented with 10 % heat-inactivated Gold fetal bovine serum (#FBS-HI-11A, 
Capricorn, Germany), and Penicillin/Streptomycin (#P4333, Sigma Aldrich, Darmstadt, Germany) 
at 37 °C and 5 % CO2 until 80 % confluency. Passaging was performed at least once a week by 
gentle trypsinization.  
4.3.2 Transduction of HEK293 cells with OTR gene variants 
For a stable integration of the OTR variants in the genome, moloney murine leukemia virus 
(MMLV) vectors were designed using VectorBuilder (Neu-Isenburg, Germany) and HEK293 cells 
were transduced according to the manufacturer’s protocol. Wildtype MMLV virus has a plus-
strand linear RNA genome. An MMLV retroviral vector is first constructed as a plasmid in E. coli. 
It is then transfected into packaging cells along with several helper plasmids. Inside the packaging 
cells, vector DNA located between the two long terminal repeats (LTRs) is transcribed into RNA, 
and viral proteins expressed by the helper plasmids further package the RNA into the virus. When 
the virus is added to target cells, the RNA cargo is shuttled into cells where it is reversely 
transcribed into DNA and randomly integrated in the host genome. The OTR gene that was placed 
in-between the two LTRs during vector construction is permanently inserted into host DNA 
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alongside the rest of the viral genome. Vector construction, amplification and packaging has been 
executed by VectorBuilder (Neu-Isenburg, Germany). 
The constructs contained the respective human OTR gene (transcript variant 1, accession number 
NM_000916.3) or the SNP-containing variant (rs4686302) and an N-terminal 3xFLAG tag 
conjugated to the gene. To examine the transduction efficiency, and the further inheritance of 
the transduced genome, a control virus expressing EGFP was used. Genetically unmodified 
HEK293 cells served as reference for all transductions. 
4.3.3 Establishment of monoclonal cell lines expressing the OTR 
In order to reduce the variability among the resulting polyclonal cell populations, we aimed to 
use monoclonal cell lines for our approaches. Single cell sorting was performed by FACS at the 
Central FACS Facility of the Regensburg Center for Interventional Immunology. Cells were stained 
with an anti-DDDDK tag antibody conjugated with Phycoerythrin (ab72469, abcam, Cambridge, 
UK) prior to the flow cytometry. Positively transduced cells were deposited individually in a 96-
well plate and re-cultured for several weeks using a mixture of fresh and conditioned medium. 
Conditioned medium was generated by cultivating HEK293 cells in normal growth medium to 
near confluency. The medium now containing growth factors released by the cell layer was 
removed and stored at 4°C until further use. 
4.3.4 Whole-genome sequencing 
Two cell lines, one expressing the reference and one the SNP-containing OTR gene, were chosen 
based on their expression levels of the OTR protein, validated by FLAG-tag Western Blot. For 
further analysis, including the genomic integration site of the constructs, cells were sent to the 
company CeGaT GmbH (Tübingen) for whole-genome sequencing and subsequent bioinformatics 
analyses. 
4.3.5 Cytosolic calcium imaging with Fura-2/AM 
The basal cytosolic Ca2+ amount and the OT-induced cellular Ca2+ response were assessed using 
the ratiometric Ca2+ indicator Fura-2/AM. 7 × 105 cells were seeded on sterile glass coverslips 
(diameter 25 mm), placed in 6-well plates, and grown overnight in medium, humidified air and 5 
% CO2. On the next day, cells were loaded with 2 µM Fura-2/AM and Pluronic F127 in OptiMEM 
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(Life Technologies, Carlsbad, USA) for 30 min at 37 °C, humidified air and 5 % CO2. For imaging, 
the loading medium was replaced by assay buffer (140 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mM 
MgSO4, 10 mM glucose, and 10 mM HEPES) and the coverslip was mounted in a chamber on the 
inverted microscope (ZEISS Observer Z.1, Jena, Germany) equipped with a Fluar 40/1.3 objective 
lens (ZEISS). Cells were illuminated with light of 340 and 380 nm (BP 340/30 HE, BP 387/15 HE) 
using a fast wavelength switching and excitation device (Lambda DG-4, Sutter Instrument, 
Novato, USA), and fluorescence was detected at 510 nm (BP 510/90 HE and FT 409) using an 
AxioCam MRm LCD camera (ZEISS). The cytosolic Ca2+ level was analyzed as fluorescence ratio at 
510 nm after excitation at 340 and 380 nm. Solutions (Ringer +/- Ca2+) and OT (final concentration 
100 nM) were applied with a perfusion system. Regions of interest were drawn over selected 
cells in the visual field using the Zen imaging software (ZEISS) and FIJI/ImageJ. Ca2+ traces were 
plotted with the Origin Software (OriginLab, version 9.7.0.188) evaluating the basal cytosolic Ca2+, 
area under the curve, amplitude as well as full width half maximum. 
4.3.6 Protein isolation and Western blot 
The expression or phosphorylation levels of the proteins FLAG and ERK1/2 were detected via 
Western blot analysis.  For the extraction of proteins, cells were scraped in 1 mL ice-cold PBS 
using a cell scraper (#83.1830, Sarstedt, Nümbrecht, Germany), centrifuged and resuspended in 
100 µl RIPA lysis buffer (R0278, Sigma Aldrich, Darmstadt, Germany) supplemented with HALT 
inhibitor and EDTA (78444, Thermo Fisher, Waltham, MA) to obtain whole cell lysates. Western 
blotting was performed as previously described in (Meyer et al., 2018). 20 to 30 µg of whole cell 
extract were loaded and separated in a 12 % Mini PROTEAN or Criterion TGX Stainfree gel (Bio-
Rad, Feldkirchen, Germany), respectively. Semi-dry blotting of separated proteins to 
nitrocellulose membranes was conducted using the FAST Blotter by Bio-Rad. Stainfree total 
protein method by Bio-Rad served as protein loading control. Specific antibodies for anti-DDDDK 
(ab1162, abcam, Cambridge, UK) revealed expression levels of the protein of interest, as well as 
phosphorylation levels of ERK1/2. 
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4.3.7 RNA Sequencing and gene ontology analysis 
Effects of the receptor variant on the cellular transcriptome were analyzed by RNA Sequencing. 
Three samples of each cell line were stimulated with 100 nM OT for 1 hour and sent to the 
company CeGaT GmbH (Tübingen) for performance and evaluation of the transcriptome, 
including a subsequent GO analysis of differentially regulated genes between the two distinct 
OTR variant containing cell lines. For RNA sequencing, trimmed raw reads were aligned to the 
human reference genome (hg19) using STAR (version 2.5.2b). Differential expression analysis 
between groups was performed with DESeq2 (version 1.24.0) in R (version 3.6.1) (R Core Team 
2015). DESeq2 uses a negative binomial generalized linear model to test for differential 
expression based on gene counts. The list of genes associated with ASD was downloaded from 
the SFARI database (https://gene.sfari.org/autdb/GS_Home.do) and compared to the list of 
differentially regulated genes obtained from the transcriptome analysis. Additionally, genes were 
categorized according to the gene scoring module of SFARI. Genes scored as category 1 show 
high confidence, meaning each of these genes has been clearly implicated in ASD, and meet the 
most rigorous threshold of genome-wide significance. Category 2 represents strong candidates 
that are uniquely implicated by WGAS reaching genome-wide significance and that have most 
likely a functional effect. In category 3, genes with a suggestive evidence with certain proof from 
significant but unreplicated studies are listed. For GO analysis, significantly down- and up-
regulated genes were extracted using a log2 fold change of 0.58. Using the R-package GOfuncR 
(Grote, 2020) we identified significantly enriched and depleted GO terms for up- and down-
regulated genes separately, as well as in the combined dataset. GOfuncR uses a hypergeometric 
test to identify over- and underrepresented GO terms in a set of genes given the distribution of 
GO terms in the background (e.g. the human transcriptome). 
4.3.8 Cycloheximide protein degradation assay 
The turnover of the OTR protein was determined using cycloheximide (CHX)-mediated inhibition 
of de novo protein synthesis. Cells were seeded, and subsequently treated with 20 μg/ml CHX 
(Sigma, Taufkirchen, Germany) for 0-24 hours. Proteins were isolated with RIPA and Western Blot 
analysis was performed. The expression of 3x-FLAG was analyzed in whole protein lysate. 
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4.3.9  Statistical analysis 
Statistical analyses was performed using Sigma Plot (version 13.0, Systat Software). Data was 
analyzed either by t-test or two-way ANOVA followed by Tukey post hoc test as indicated in the 
figure legends or text. Statistical significance was accepted at p < 0.05. Due to the large number 
of genes in the RNA sequencing data set, Benjamini-Hochberg multiple-testing correction was 
used for controlling false discovery rate (padj, adjusted p-value). In Ca2+ imaging experiments, n 
represents number of cells/traces, in Western Blots, n represents number of cell lysates. Data 
are presented as mean + standard error of the mean. 
4.4 Results 
Whole genome sequencing of the two human HEK293 cell lines expressing an OTR variant was 
performed in order to validate the successful transduction and to identify the localization of 
insertion sites (Table 4). The genomic analysis revealed that the OTR WT construct was inserted 
on chromosome 8 at the indicated position, which is located within the MYC gene. The OTR SNP 
construct was inserted twice on chromosome 6 at the two indicated positions, which are located 
within the NUDT3 and USP45 gene. 
Table 4. Identified insertion points of the oxytocin receptor (OTR) gene constructs in human HEK293 cells. 
Cell line Chromosome Position Gene 
OTR WT 8 128799928 MYC 
OTR A218T 6 34292480 NUDT3 
6 99962623 USP45 
 
Additionally, for each insertion point, ten genes upstream and downstream of the location were 
extracted and analyzed for potential dysregulations by the insertion. Comparison with the 
differentially expressed genes from the transcriptomic analysis revealed several genes close to 
the insertion points that are significantly differently regulated between the two cell lines  (Table 
5).  
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Table 5. Differentially expressed genes and their p-value close to the insertion points. 
Insertion point Gene Adjusted p-value 
MYC MYC 5.24e-33 
FAM49B 0.025 
LPCAT1 7.66e-23 
FAM84B 0.0005 
ASAP1 0.01 
NUDT3 SCUBE3 1.16e-5 
SNRPC 0.006 
GRM4 0.0007 
ITPR3 1.35e-32 
UQCC2 0.004 
HMGA1 6.36e-16 
USP45 MMS22L 0.04 
POU3F2 0.04 
FBXL4 5.73e-5 
COQ3 1.73e-5 
PNISR 5.99e-26 
USP45 0.02 
CCNC 1.94e-7 
SIM1 7.04e-5 
ASCC3 0.0001 
 
The double gene insertion in the OTR A218T cell line results in a 1.36-fold upregulation of the 
OTR transcript, which was confirmed by RNA Sequencing, and a 1.78-fold upregulation of the 
protein compared to the OTR WT expressing cells (Figure 13A-C). Due to a lack of specificity of 
OTR antibodies (Yoshida et al., 2009), we detected OTR expression via the 3x-FLAG tag, whose 
specificity could be confirmed in a control experiment (data not shown). 
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Furthermore, we aimed to analyze the stability of the OTR variants using the CHX chase protein 
degradation assay. The OTR protein stability was assessed by incubating cells for 0 to 24 hours 
with 20 μg/ml of CHX, a well-known inhibitor of eukaryotic translation (Figure 13E). The OTR 
protein expression was quantified at different time points after CHX treatment as percentage of 
the initial protein level (0 min of CHX treatment) and detected via the 3xFLAG-tag. Results from 
protein degradation analysis suggest that the OTR A218T protein is significantly more stable than 
the OTR WT variant (Figure 13D). 
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Figure 13. (A) Gene and resulting protein sequence of the wildtype (WT) and mutant OTR variant A218T. The 
mutation of the base cytosine (WT) to thymine (SNP) in the gene sequences leads to an amino acid exchange of in 
the protein sequence. The change in the nucleotide triplet codes for a threonine (SNP) instead on an alanine (WT) 
in the OTR protein. (B) Relative mRNA expression level of the oxytocin receptor (OTR) revealed by RNA sequencing 
in cells expressing the A218T variant compared to OTR WT. The OTR mRNA level is significantly higher in the A218T 
compared to WT cells. * padj < 0.001. (C) Relative protein expression of 3x-FLAG tag reflecting the OTR expression in 
the WT compared to A218T cell line. T-test revealed a significant increased protein expression of the OTR in the 
A218T cells. n = 6. * p = 0.005. (D) Protein stability evaluated by cycloheximide (CHX) assay. HEK293 cells expressing 
either the WT OTR or OTR mutant A218T were treated with CHX (20 μg/ml) for the indicated times (in min), and 
3xFLAG-tag was detected in Western Blot. FLAG levels after treatment with CHX were quantified as percentage of 
the initial FLAG protein level (0 min of CHX treatment). Two-way ANOVA revealed a significant effect between the 
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cell lines. CHX treatment leads to a significant reduction of the initial protein level beginning after 30 min incubation 
in both cell lines. There is no significant interaction between cell line and treatment. Data are shown as mean ± SEM. 
n = 4-6 for each data point. * p (cell line) = 0.002. * p (treatment) < 0.001. (E) Scheme of CHX inhibition effect on 
protein translation. The schematic art pieces used in this figure were provided by Servier Medical art 
(http://servier.com/Powerpoint‐image‐bank). Servier Medical Art by Servier is licensed under a Creative Commons 
Attribution 3.0 Unported License. 
 
In order to study the impact of the OTR variants on the OT-induced Ca2+ influx, we performed 
Ca2+ imaging using Fura-2/AM. We evaluated the Ca2+ response of the cells in presence and 
absence of Ca2+ in the Ringer solution to elucidate the source (extra- versus intracellular, 
representative traces Figure 14A and 14B). Two-way ANOVA revealed a significantly reduced 
cytosolic Ca2+ concentration in the A218T cells compared to OTR WT under physiological 
conditions as well as in absence of extracellular Ca2+ (Figure 14C). The amplitude of the OT-
induced Ca2+ peak was lower in the OTR WT cells incubated in Ca2+-free Ringer compared to the 
A218T cells in the same medium and to the WT cells when incubated in Ca2+-containing Ringer 
solution (Figure 14D). The area under the curve revealed a cell-line specific main effect showing 
a higher increase in the cytosolic Ca2+ concentration upon OT stimulation in the OTR A218T 
compared to the WT cell line (Figure 14E). The full width at half maximum (FWHM), which reflects 
the kinetics of the OT-induced Ca2+ response, differed significantly between the two cell lines 
irrespective from the bathing solution, indicating a prolonged OT-induced Ca2+ response in the 
A218T cells (Figure 14F).  
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Figure 14. (A) and (B) Representative Ca2+-traces of cells encoding either the OTR wildtype (WT) or A218T variant 
after stimulation with 100 nM oxytocin (OT) in presence (grey line) or absence (red line) of Ca2+ in Ringer. Time shift 
in (B) is not representative. (C) Basal Fura-2 340 nm/380 nm ratios of the OTR WT and OTR mutant cell line. The cell 
line encoding the OTR A218T variant has a significantly reduced concentration of basal cytosolic Ca2+ compared to 
OTR WT under both, physiological and Ca2+-free conditions. * p < 0.001. (D) Fura-2 340 nm/380 nm ratio amplitudes 
of the OTR WT and OTR A218T cell line after application of 100 nM OT. The maximal amplitude of OT-induced Ca2+-
peaks in OTR WT cells is significantly reduced in absence of extracellular Ca2+ in comparison to the generated peak 
under physiological conditions as well as to the amplitude of the OTR A218T mutant under the Ca2+-free conditions. 
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* p < 0.001. Moreover, there is a statistically significant interaction between cell line and treatment (+/- Ca2+ in 
Ringer), * p = 0.01. (E) The area under the curve is significantly increased in OTR A218T compared to OTR WT cells 
under both conditions. The area under the curve is calculated and shown as an integral over time above the baseline. 
* p < 0.001. (F) Two-way ANOVA revealed a main effect between the cell lines regarding the full width half maximum 
(FWHM) in the OTR A218T cells reflecting a prolonged Ca2+ response. * p = 0.02. Sample size for graphs C, D, E and 
F: n (OTR WT + Ringer) = 91, n (OTR WT + Ca2+-free Ringer) = 96, n (OTR A218T + Ringer) = 63, n (OTR A218T + Ca2+-
free Ringer) = 89. 
 
To assess MAPK pathway activation, the basal and OT-induced phosphorylation levels of ERK1/2 
were assessed by Western Blot. Incubation of the OTR WT or OTR A218T cells with 100 nM OT 
over a time course of one hour resulted in a significant increased phosphorylation of ERK2 as it 
has been already shown by several studies (Blume et al., 2008; Jurek et al., 2012) (Figure 15B). 
No significant effect of OT-induced phosphorylation of ERK1 could be detected, which might be 
due to the small sample size (Figure 15A). However, there was a trend towards a main effect 
between the cell lines, with a significant effect after 60 min. Since 60 min of OT-incubation 
revealed the overall strongest effects, the stimulation was repeated with greater sample size. A 
direct comparison of the two cell lines on a basal level or after one hour incubation with 100 nM 
OT revealed a significant reduced MAPK activation in the OTR A218T cells reflected by both, 
pERK1 (Figure 15C) and pERK2 (Figure 15D) levels. 
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Figure 15. (A) Timeline of ERK1 phosphorylation in OTR WT and OTR A218T cells after stimulation with 100 nM 
oxytocin (OT) for 10, 30 or 60 min. Two-way ANOVA did not reveal a significant effect between the cell lines in the 
ERK1 phosphorylation, although there was a trend (p = 0.052). n = 5 per group. (B) Timeline of ERK2 phosphorylation 
in OTR WT and OTR A218T cells after stimulation with 100 nM OT for 10, 30 or 60 min. There was a significant effect 
in the OT treatment, but no difference in them time pattern of phosphorylation between the cell lines. * p (60 min 
vs. 0 min) = 0.022. n = 5 per group. (C) and (D) Relative phosphorylation of ERK1 (C) and ERK2 (D) in OTR WT and 
A218T cells after treatment with 100 nM OT for 1h. Direct comparison of the cell lines revealed that the OTR A218T 
cells show a lower phosphorylation level than the OTR WT cells independent from the treatment present (VEH/OT). 
* p < 0.049. n = 10 per group. 
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In order to analyze differences in target gene expression, three samples per cell line that have 
been stimulated with 100 nM OT for one hour were sent for RNA sequencing, which revealed a 
large cohort of significantly regulated genes in OT-stimulated OTR A218T cells, when compared 
to expression levels in stimulated OTR WT cells. One sample in the OTR WT group had to be 
removed because of a strong deviation in the hierarchical clustering of the samples according to 
the similarity of their expression data. 
When filtered by corrected significance padj < 0.05, a number of 7823 genes were differentially 
regulated (Table 6). The top 100 differentially expressed genes are listed in a heatmap (Figure 
16). 
 
Table 6. Statistically significant differentially expressed genes in comparison group A vs. group B. 
Group A Group B Number of significant regulated genes (padj<0.05) 
OTR A218T OTR WT 7823 
 
429 of those genes have been identified as ASD risk genes after comparison with the database 
provided by SFARI. Additionally, the filtered genes have been classified according to the gene 
scoring module in different categories ranging from 1 (high confidence) to 3 (suggestive 
evidence). 107 differentially expressed genes have fallen in category 1 of the ASD scoring, the 50 
most frequently reported are listed Table 7. 
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Figure 16. Heatmap of the top 100 differentially expressed genes in the OTR A218T compared to OTR WT cells. Color-
coded values represent the log2FoldChange expression after normalization and averaging over the biological 
replicates in each cell line. Genes (rows) and cell lines (columns) were clustered hierarchically according to similarity 
between expression levels. 
 
Table 7. The most frequently reported ASD-associated genes, which are differentially expressed in OTR A218T 
compared to OTR WT cells, with full gene name, the number (#) of reports, and log2FoldChange from transcriptome 
analysis of the cell lines. Underlined with a color code from red to blue, positive value indicates a higher expression 
in A218T compared to WT, while a negative value refers to a reduced expression. 
Gene Gene name 
# of 
reports log2FoldChange 
SHANK3 SH3 and multiple ankyrin repeat domains 3 84 -0.52 
MECP2 Methyl CpG binding protein 2 82 0.27 
PTEN Phosphatase and tensin homolog 62 0.25 
SYNGAP1 Synaptic Ras GTPase activating protein 1 56 0.42 
CHD8 Chromodomain helicase DNA binding protein 8 54 0.17 
FOXP1 Forkhead box P1 50 0.28 
CACNA1C Calcium channel, voltage-dependent, L type, alpha 1C subunit 47 -2.17 
ARID1B AT-rich interaction domain 1B 47 0.20 
ANKRD11 Ankyrin repeat domain 11 45 0.21 
DYRK1A Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A 45 0.33 
TCF4 Transcription factor 4 45 0.56 
FOXP2 Forkhead box P2 43 0.63 
STXBP1 Syntaxin binding protein 1 42 -0.75 
ADNP Activity-dependent neuroprotector homeobox 41 0.28 
CHD2 Chromodomain helicase DNA binding protein 2 40 0.43 
GABRB3 Gamma-aminobutyric acid (GABA) A receptor, beta 3 38 -4.78 
SHANK2 SH3 and multiple ankyrin repeat domains 2 35 -2.41 
SCN8A Sodium channel, voltage gated, type VIII, alpha subunit 35 0.50 
MBD5 Methyl-CpG binding domain protein 5 35 0.62 
PCDH19 Protocadherin 19 34 -7.10 
MED13L Mediator complex subunit 13-like 33 0.19 
POGZ Pogo transposable element with ZNF domain 33 0.51 
TSC2 Tuberous sclerosis 2 32 -0.20 
CHD7 Chromodomain helicase DNA binding protein 7 28 0.28 
UBE3A Ubiquitin protein ligase E3A 27 0.15 
IQSEC2 IQ motif and Sec7 domain 2 26 -1.62 
TRIO Trio Rho guanine nucleotide exchange factor 26 0.16 
ANK3 Ankyrin 3 26 0.20 
FOXG1 Forkhead box G1 26 0.40 
ASXL3 Additional sex combs like 3 25 0.29 
SETD5 SET domain containing 5 25 0.46 
NF1 Neurofibromin 1 24 -0.14 
ZBTB20 Zinc finger and BTB domain containing 20 23 1.08 
RAI1 Retinoic acid induced 1 22 -0.39 
TSC1 Tuberous sclerosis 1 21 -0.32 
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CUL3 Cullin 3 21 0.15 
TBL1XR1 Transducin beta like 1 X-linked receptor 1 21 0.21 
ATRX Alpha thalassemia/mental retardation syndrome X-linked 21 0.31 
VPS13B Vacuolar protein sorting 13 homolog B (yeast) 20 0.21 
DEAF1 DEAF1 transcription factor 19 -0.15 
DDX3X DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked 19 0.20 
NBEA Neurobeachin 19 0.29 
WAC WW domain containing adaptor with coiled-coil 19 0.33 
KMT2C Lysine (K)-specific methyltransferase 2C 18 0.16 
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 18 0.42 
NRXN3 Neurexin 3 18 0.71 
ARX Aristaless related homeobox 17 -1.24 
NSD1 Nuclear receptor binding SET domain protein 1 17 0.14 
ANK2 Ankyrin 2, neuronal 17 0.32 
 
GO analysis of the differentially expressed genes between the OTR WT and A218T cell line was 
conducted using a log2FoldChange cutoff of 1.5. The analysis was done using only the up-
regulated genes, only the down-regulated genes and up- and down-regulated genes together 
(Table 8). 
Table 8. Number (#) of analyzed genes and enriched gene ontology (GO) terms. GO terms were identified for genes 
significantly up- and down-regulated in OTR A218T compared to WT cells separately, as well as in the combined 
dataset. 
Dataset # of significant 
genes 
Genes with GO 
annotation (in %) 
Biological 
processes 
Cellular 
components 
Molecular 
functions 
Up-
regulated 
804 61.94 50 14 19 
Down-
regulated 
1803 81.2 306 92 26 
Both 2607 75.26 286 90 23 
 
Not all human genes have been annotated yet, therefore only a certain percentage of the 
differentially expressed genes have a GO annotation. However, most genes with an annotation 
are assigned to several GO terms. Since the GO has a tree-like structure, there is a redundancy in 
the data. In line with the results obtained in this study and in previous publications of our group, 
a few GO terms were selected from the huge dataset and assigned to OTR-coupled and/or ASD-
related processes (Table 9). 
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Table 9. Selection of gene ontology (GO) terms up- and downregulated in OTR A218T vs WT cells with identification 
number assigned to oxytocin receptor-coupled processes.  
GO term GO ID 
Receptor binding 
and stability 
oxytocin receptor binding GO:0031855 
cellular response to cycloheximide GO:0071409 
Calcium signaling calcium-mediated signaling GO:0019722 
cellular response to calcium ion GO:0071277 
calcium ion homeostasis GO:0055074 
calcium ion transport GO:0006816 
calcium ion transmembrane import into cytosol GO:0097553 
calcium ion transmembrane transport GO:0070588 
calcium ion transmembrane transport via high voltage-gated 
calcium channel 
GO:0061577 
calcium ion transmembrane transport via low voltage-gated 
calcium channel 
GO:0090676 
MAPK signaling MAPK cascade GO:0000165 
p38 MAPK cascade GO:0038066 
activation of MAPK activity GO:0000187 
activation of MAPKK activity GO:0000186 
activation of MAPKKK activity GO:0000185 
Connectivity cell-cell adhesion GO:0098609 
cell-cell adhesion mediated by integrin GO:0033631 
cell-cell signaling GO:0007267 
integrin-mediated signaling pathway GO:0007229 
Cellular 
morphology 
cytoskeleton organization GO:0007010 
actin cytoskeleton organization GO:0030036 
intermediate filament organization GO:0045109 
microtubule cytoskeleton organization GO:0000226 
cell morphogenesis GO:0000902 
dendrite extension GO:0097484 
axon extension GO:0048675 
Mitochondrial 
function 
mitochondrial calcium ion homeostasis GO:0051560 
mitochondrial calcium ion transmembrane transport GO:0006851 
mitochondrial ATP synthesis coupled electron transport GO:0042775 
mitochondrial ATP synthesis coupled proton transport GO:0042776 
mitochondrial respiratory chain complex assembly GO:0033108 
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4.5 Discussion 
In this study, we evaluated the cellular effects caused by genetic variations affecting the OTR 
gene. We aimed to assess the functional relevance of the non-synonymous SNP rs4686302, which 
has been associated with core symptoms of ASD, cognition deficits, empathy, and preterm birth 
(Wu et al., 2012; Francis et al., 2016; Kalyoncu et al., 2019; Kim et al., 2013). Our approach of 
using MMLVs to permanently integrate the OTR gene into the HEK293 genome granted us with 
a stable expression level in the monoclonal cell line, however, it bears the risk of unwanted 
disruption of host genes. Having analyzed the data generated by the whole genome sequencing, 
we identified the integration site(s) of the OTR, and thereby recognized a few target genes that 
might have been affected for technical reasons instead of OT treatment. In the OTR WT cell line, 
the construct was integrated into the host genome on chromosome 8, and in the OTR A218T cells 
twice on chromosome 6. This affected three different genes, namely MYC, NUDT3, and USP45. 
Additionally, differentially regulated genes that are located close to the insertion sites were listed 
and should be carefully interpreted. The double insertion of the SNP construct resulting in a 
higher expression of OTR mRNA and protein bears clinical relevance. An increased prevalence of 
CNVs, including duplications or deletions of certain genes, have been found in individuals with 
ASD. One case study confirming such a variation affecting the OTR gene, presents a 9-year old 
boy with pervasive developmental disorder suffering from obesity and behavioral issues, 
underscoring the role of an OTR gene duplication with consecutive overexpression in ASD (Bittel 
et al., 2006). This level of precise in-depth genomic information is not addressed in the majority 
of such studies, and has rarely been discussed. 
The SNP rs4686302 is located within the coding sequence of Exon 3 and leads to an 
alanine/threonine amino acid exchange. Such exchange in the amino acid sequence is prone to 
induce self-aggregation of the resulting peptide due to the inherent preferences of alanine to 
form helices and of threonine to support beta-sheet structures (Podoly et al., 2010). Interestingly, 
we have found stabilizing effects of this SNP on receptor protein stability. Using CHX as a potent 
translational inhibitor, we could provide evidence that the OTR A218T variant shows significantly 
longer half-life kinetics suggesting an increased protein stability. Because of this conformational 
change leading to an enhanced stability, receptor properties like ligand binding might be 
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affected, as it has been recently described for rs4686302 (Fueg et al., 2019). In line with the 
already reported increased sensitivity to OT, we found that the OT-induced increase in 
intracellular Ca2+ levels is higher in OTR A218T cells compared to the OTR WT cells. Moreover, 
the kinetic profile of the Ca2+ response indicates a prolonged signal duration in the OTR A218T 
cells. This suggests that the neuroprotective strategy to prevent Ca2+ cytotoxicity, i.e. a cell’s 
mechanism of shutting down Ca2+ channels in order to stop Ca2+ entry (Duncan et al., 2010), 
might be compromised when the OTR A218T variant is expressed. Additionally, WT and A218T 
cells show differences with respect to the Ca2+ source they mainly rely on. While the OT-evoked 
Ca2+ increase in the cytoplasm of OTR WT cells is highly dependent on influx from the extracellular 
space, the signal in OTR A218T cells is maintained by the release from intracellular Ca2+ stores. 
Since several Ca2+-gated channels in the plasma membrane of the cell line expressing the mutant 
OTR A218T are downregulated, the use of intracellular sources might have compensatory 
reasons. Particularly noteworthy in this context is the TRPC6, being strongest downregulated by 
a factor of 9.35. This was accompanied by a similar, but less pronounced downregulation of 
TRPC3. TRPC3 is known to form a complex with TRPC6 (Tang et al., 2018). Disruption of TRPC6 
expression has been associated with ASD (Griesi-Oliveira et al., 2015). In addition to that, the 
alpha 1C subunit of the voltage-gated L-type calcium channel (CACNA1C), which is among the 
most prominent ASD-associated genes, was downregulated by a factor of 2.17 in the OTR A218T 
cells. In line with the consequently reduced permeability for Ca2+, lower basal levels of cytosolic 
Ca2+ have been detected in the OTR A218T cells. The observed differences in Ca2+ dynamics might 
play an important role in maintaining downstream signal specificity, such as the MAPK cascade, 
and thereby, influence the regulation of ERK-dependent cellular processes. 
Stimulation with 100 nM OT for 60 min revealed a significantly reduced MAPK pathway activation 
in the OTR A218T compared to the OTR WT cells. Since the anxiolytic effect of OT is mediated via 
the phosphorylation of ERK1/2 (Blume et al., 2008; Jurek et al., 2012), we hypothesize that the 
attenuated phosphorylation level in the OTR A218T cells could, to some extent, account for 
comorbid anxiety disorders occurring in some cases of ASD. Furthermore, the diminished activity 
of the ERK1/2 pathway impacts transcriptional regulation by downstream transcription factors. 
Whether gene transcription is up- or downregulated depends on the transcription factor and its 
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phosphorylation site, e.g. MEF2A is pERK1/2-dependent and inhibits gene transcription upon 
S408 phosphorylation, but activates gene transcription upon Thr312/319 phosphorylation 
(Meyer et al., 2018; Potthoff and Olson, 2007). We have mapped changes in the transcriptome 
of OTR WT versus OTR A218T by means of RNA-Sequencing. As both cell line derive from the 
same mother-cell line, changes in the transcriptome can be traced back to the induced genomic 
alterations. The transcriptome analysis revealed a large cohort of significantly regulated genes in 
OT-stimulated OTR A218T cells, when compared to expression levels in stimulated OTR WT cells. 
When filtered by corrected significance padj < 0.05, a number of 7823 genes were differentially 
regulated. Comparison with ASD risk genes revealed that 429 genes among them have been 
associated with ASD, providing a potential molecular link between the A218T variant and a 
psychopathological phenotype. 
In summary, we have investigated the molecular and cellular effects of OTR variants, and were 
able to unravel the chain of intracellular events that are ultimately causative for associated 
behavioral phenotypes. The genetic OTR variant A218T causes enhanced receptor stability, 
altered Ca2+ dynamics, reduced MAPK signaling, and up- and downregulations of several ASD-
related target genes. The changes in the transcriptome affect several ASD-associated cellular 
processes as confirmed by GO analysis. These dysregulations are suggested to underlie the 
behavioral abnormalities of ASD, so understanding the chain of intracellular events caused by the 
OTR SNP and gene duplication might provide us with a “master-regulator” in the ASD-pathway 
that could be exploited for clinical treatment options. 
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5 General discussion 
This section aims to put the publications (section 2, 3 and 4) into context with focus on the 
implications, relevance, and perspectives related to the findings described. 
The studies performed during the course of my thesis yielded new insights in the cellular 
processes and their molecular underpinnings following OTR activation. The results acquire 
greater importance by referring to the cellular adaptations under pathological conditions like 
ASD. In patients suffering from the severe neurodevelopmental disorder ASD, a number of 
alterations in the brain at different levels have been observed that encompass neurite outgrowth, 
the formation and maintenance of synapses, neuronal connectivity, plasticity, and mitochondrial 
dysfunction (Gilbert and Man, 2017; Nguyen et al., 2018a; Supekar et al., 2013; Siddiqui et al., 
2016). In the following part, I will discuss my main findings referring to the molecular adaptations 
underlying the neurodevelopmental disorder ASD. 
5.1 MEF2A as major regulator of OT-induced effects 
In this thesis, I provide evidence that OT leads to morphological alterations in hypothalamic 
neurons. We could show that OT stimulation leads to a neurite retraction via the MAPK pathway 
and a subsequent activation of the transcription factor isoform MEF2A by a dephosphorylation 
at S408. 
In another hypothalamic cell line that does not express MEF2A endogenously, OT exhibited 
opposing effects by inducing neurite outgrowth. Based on my first publication, I could extend the 
mechanistic insight underlying OT-induced morphological alterations in neurons. The basal 
expression and activation status of MEF2A turned out to be the decisive factors determining the 
morphological response to OT, i.e. neurite elongation or retraction. While a knockout of MEF2A 
induced neurite elongation, a knockin resulted in a reduced neurite length after OT stimulation.  
This implies a major role for MEF2A as regulator of OT-induced effects as well as basic cellular 
events. The family of MEF2 transcription factors regulate a number of genes important for the 
brain development and synaptogenesis. It has been shown that a MEF2 overexpression reduces 
the number of synapses, while a knockout induces synaptogenesis, which results in an autistic-
like phenotype in mice (Lipton et al., 2009; Tu et al., 2017). 
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In addition to that, I could identify the phosphatase CaN as novel upstream regulator of MEF2A 
in neurons, being responsible for its activation and by that, enabling the shift in the morphological 
response. In this regard, MEF2A S408 could be confirmed as the critical phosphorylation site, 
being validated by a control experiment, where the serine was exchanged with the  
phosphomimetic amino acid aspartate (S408D), leading to a loss of function of MEF2A. Since 
neuronal morphology builds up the base for cellular connectivity and plasticity, these were the 
processes addressed next.  
The integrin family of cell adhesion receptors and their ligands play essential roles in the control 
of several processes regulating neuronal connectivity (Lilja and Ivaska, 2018). The 
transmembrane receptors are responsible for cell–ECM interactions and regulating cell–cell 
interactions. Although their role in the CNS is not well understood so far, one receptor variant of 
the integrin family, integrin ß3, has been associated with ASD risk (Dohn et al., 2017; Napolioni 
et al., 2011). Moreover, a plethora of so-called ASD risk genes has been linked to alterations in 
integrin signaling (Lilja and Ivaska, 2018; Schuch et al., 2014). I identified one member of the 
integrins, integrin ß1, to be significantly downregulated in MEF2A knockout cells, pointing toward 
an increased neuronal connectivity in those cells given the reduced cell adhesion and neurite 
elongation. With ASD being a developmental disorder, the decrease of neonatal neuronal 
hyperconnectivity is dysregulated at a certain point, causing a state of persistent 
hyperconnectivity into adulthood (Supekar et al., 2013; Zaslavsky et al., 2019; Tang et al., 2014; 
Zhang et al., 2016). The state of hyperconnectivity affects various projections on the whole-brain 
and subsystems level. In line with that, the grade of hyperconnectivity has been positively 
correlated with symptom severity in ASD, in detail, children with a higher functional connectivity 
exhibited more severe social deficits (Supekar et al., 2013).  
Neurons have a high energy demand and adaptations in their morphology, connectivity, and 
plasticity are highly sensitive to energy limitations (Vergara et al., 2019). By analyzing 
mitochondrial function, I could provide evidence that MEF2A is a major regulator of respiratory 
function of mitochondria, and therefore energy supply, in neurons. The respiratory function and 
spare respiratory capacity was significantly increased in MEF2A knockout cells. As a result, the 
amount of supplied energy reflected by the cellular ATP content was elevated in the cells lacking 
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the transcription factor MEF2A compared to those expressing it. In line with my data, a large 
proportion of ASD patients suffer from mitochondrial dysfunction and abnormalities in energy 
generation (Giulivi et al., 2010; Siddiqui et al., 2016). Already in 1985, Coleman and Blass 
proposed the first hypothesis of ASD coinciding with an underlying comorbidity of mitochondrial 
dysfunction (Coleman and Blass, 1985).  
Taken together, the results from my first two publications (Chapter 2 and 3) imply a central role 
for MEF2 in ASD and its concomitant adaptations. In the minireview “Anxiolytic and Anxiogenic? 
How the Transcription Factor MEF2 Might Explain the Manifold Behavioral Effects of Oxytocin.” 
we suggest that the MEF2-mediated effects on morphology and connectivity in OTR-positive 
neurons might consequently lead to a shift in the connectivity between brain regions of the so-
called salience network. This brain network plays a central role in the regulation of complex 
functions like communication, social behavior, and self-awareness. We hypothesize that MEF2 
activity upon OTR activation induces changes on a cellular and subsequently on a network level. 
As a result of those changes in the salience network, OT can cause alleviating or adverse 
behavioral responses depending on the emotional context of external stimuli (Figure 17) (Jurek 
and Meyer, 2020). 
 
 
Figure 17. Graphical Abstract adapted from the review “Anxiolytic and Anxiogenic? How the Transcription Factor 
MEF2 Might Explain the Manifold Behavioral Effects of Oxytocin.” (Jurek and Meyer, 2020). 
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Dysfunctions affecting the salience network have been detected in a variety of psychiatric 
disorders, including anxiety disorders, post-traumatic stress disorder, schizophrenia, or ASD 
(Palaniyappan et al., 2012; Green et al., 2016; Akiki et al., 2017; Geng et al., 2015).  
Proceeding on the assumption that MEF2 constitutes a central node point in the regulation of 
several cellular processes important for the mental health, and given the inconsistencies in the 
clinical studies testing OT as potential treatment for ASD, yields the need to investigate the origin 
of those irregularities. One major factor determining the predisposition to diseases or the 
response to a drug treatment, are genetic variations. 
5.2 The role of genetic variations affecting the OTR gene 
Many psychiatric diseases have a strong genetic component reflected by the heritability 
measures ranging from 30 % to 80 % for the majority of them (Zuchner et al., 2007). The cellular 
maladaptation found in ASD patients are mostly based on the genetic background of the 
individuals, as suggested by twin studies that reveal the heritability estimations to be over 80 % 
(Sandin et al., 2017). The risk for a newborn child is more than 10-fold higher if a previous sibling 
suffers from ASD (Sandin et al., 2014). The variations in the human genome can appear on 
multiple scales, ranging from variances in the total chromosome number over duplications or 
deletions of genes to exchanges of single bases. 
Among those genetic factors that have been associated with ASD are SNPs in the OTR gene. The 
proportion of ASD cases explained by common genotyped SNPs is estimated to be around 17 %–
60 % (Gratten et al., 2014). The linkage between OTR SNPs and mental illness stems mainly from 
GWAS, and there are just very few molecular studies elucidating the underlying cellular effects 
(Fueg et al., 2019; Furman et al., 2011).  
Therefore, my aim was to assess the molecular effects of SNPs in the OTR gene. In the third part 
of my thesis, I investigated one common OTR variant and could provide evidence for the 
dependence of OT-induced cellular effects on the genetic background. I focused on the specific 
OTR SNP rs4686302, a non-synonymous SNP located in the third exon of the human OTR gene 
that results in an amino acid exchange of alanine to threonine at the position 218 in the OTR 
protein. In previous publications, this SNP has been associated with core characteristics of ASD, 
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social cognition deficits/attention disorders, and trait empathy in healthy persons (Francis et al., 
2016; Wu et al., 2012; Kalyoncu et al., 2019).  
For that purpose, human HEK293 cells, which do not express the OTR endogenously, were virally 
transduced with a construct either containing the reference or the SNP-containing variant of the 
OTR. For a comprehensive comparison including the identification of the genomic insertion sites 
of the transduced OTR gene in the two cell lines, a WGS was performed. The genomic analysis 
revealed the insertion of the reference gene on chromosome 8 and a double insertion of the OTR 
gene on chromosome 6 in the cell line transduced with the SNP variant. This gene duplication 
resulted in an increased mRNA and protein expression of the OTR A218T compared to the OTR 
WT. Admittedly, we cannot clearly determine if the differences found between the cell lines are 
due the SNP or to the gene duplication. However, both convey clinical relevance, as many 
neurodevelopmental disorders are associated with structural anomalies, such as duplications or 
deletions of certain sections on a chromosome and consequently thereon located genes. Those 
changes called genomic copy number variants (CNVs) account for a proportion of more than 10 
% of ASD cases (Sebat et al., 2007). Although technologies for their detection developed fast and 
became far more powerful, the interpretation of data is marked by inconsistencies and failing 
correlations between genotype and phenotype. The same CNV can cause different mental 
diseases within the same family (Sebat et al., 2009). Besides environmental and sex-specific 
factors as well as epigenetic modifications that contribute to those variations, a complex 
interaction of potentially pathogenic CNVs with SNPs might be causative (Velinov, 2019). To our 
knowledge, just two studies about CNVs affecting the OTR have been published so far. In the 
study from Gregory et al. 119 probands from multiplex autism families were analyzed. The 
genomic deletion of the OTR, previously suggested by the authors, could be confirmed only in 
one study participant and his mother (Gregory et al., 2009). In a larger proportion of the 
participants, the authors detected a hypermethylation of the OTR gene promoter, with a 
consequently reduced mRNA expression in ASD patients. In contrast, the case study from Bittel 
et al. presents a 9-year old boy with pervasive developmental disorder, delayed speech, and 
sudden onset of obesity. Genetic analysis revealed duplications of the 3p25-3p26 genomic 
region, which results in an overexpression of the OTR gene (Bittel et al., 2006). This suggests that 
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an OTR gene duplication with a consecutive OTR overexpression can be causative for a behavioral 
phenotype falling within the symptomatic classification of ASD. However, both studies highlight 
the involvement of the OTR gene variations in ASD.  
Taken together, our findings obtained by the WGS approach provide a detailed genomic 
information that is rarely addressed in the majority of such studies. In most studies, only the 
overall protein expression profile of a cell is analyzed, even though the location of inserted genes 
and possible off-target effects play a crucial role in determining the function of a cell.  
For this purpose, we isolated several genes up- and downstream of the insertion sites and 
checked if they were affected by the construct insertion in order to detect potential off-target 
effects by disrupted genes. Those genes close to the genomic insertion sites with a differential 
expression were listed and should be carefully interpreted.  The SNP rs4686302 is located within 
the coding sequence of Exon 3, and leads to an alanine/threonine amino acid exchange. 
Substitutions of alanine with threonine caused by SNPs, what occurs in various proteins, can 
induce self-aggregation into amyloid fibrils or other amyloidogenic proteins (Podoly et al., 2010). 
This is mainly due to the preferences of alanine to form helices and of threonine to support less 
stable beta-sheet structures. Surprisingly, by analyzing the receptor protein stability by CHX 
degradation assay, we could provide evidence that the OTR A218T variant shows an increased 
receptor stability. The consequently enhanced receptor availability in the plasma membrane 
would lead to an increased ligand binding, which has been recently described for rs4686302 
(Fueg et al., 2019).  
In line with that, we found that upon OTR activation the rise in intracellular Ca2+ levels is higher 
in OTR A218T compared to OTR WT cells. Additionally, we were able to detect a difference in the 
Ca2+ source. In contrast to the OTR A218T, the OTR WT cells rely more on OT-induced influx of 
Ca2+ from the extracellular space than on the release from intracellular stores. The spatio-
temporal properties and dynamics of the intracellular Ca2+ signals play an important role in 
transmitter release in classical synapses (Meinrenken et al., 2003). Furthermore, the OT-induced 
Ca2+ release from intracellular stores suffices for dendritic release of OT (Ludwig et al., 2002). As 
a consequence, dysregulations in Ca2+ signaling can have severe consequences and lead to a 
disruption of neurological function including signal transmission, excitatory-inhibitory balance 
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and synaptic plasticity, consequently contributing to the pathophysiology of ASD (Nanou et al., 
2018; Nguyen et al., 2018b).  
Furthermore, the basal cytosolic Ca2+ concentration was lower in the cells encoding the OTR 
A218T compared to the WT variant.  At any given moment, the concentration in cytosolic Ca2+ is 
determined by the balance between Ca2+ influx and efflux as well as a permanent exchange with 
internal stores. In order to keep this balance, a vast array of cellular checkpoints are controlling 
Ca2+ homeostasis, like Ca2+ binding proteins, transcriptional networks, ion channels, and ion 
exchangers in both, the plasma membrane and the membranes of mitochondria and the 
endoplasmic reticulum. Therefore, dysfunctions in Ca2+ signaling are often accompanied by 
disruptions in the Ca2+ regulating organelles. In this context, RNA sequencing revealed a plethora 
of transcripts involved in this process. Referring to Ca2+-permeable channels in the plasma 
membrane, the trpc6 was the overall most prominently downregulated transcript with a change 
by a factor of 9.35. Intriguingly, the disruption of TRPC6 has been previously associated with ASD 
(Griesi-Oliveira et al., 2015). Another variant strongly associated with ASD, is the voltage-gated 
Ca2+ channel CACNA1C, which was downregulated by a factor of 2.17 in the OTR A218T cells, 
thereby regulating cellular Ca2+ entry, neurotransmitter release and gene expression (Andrade et 
al., 2019). 
Furthermore, various genes of the endoplasmic reticulum and the mitochondria were 
differentially regulated between the two cell lines. These two organelles communicate with each 
other by generation of Ca2+ signals, forming a link between energy metabolism and signal 
transmission via changes in the cytosolic free Ca2+ concentration (Hayashi and Su, 2007; 
Patterson et al., 2004). Interestingly, the transcription factor MEF2A was identified as a transcript 
that was slightly upregulated in the cell line expressing the OTR A218T variant. Since MEF2A 
regulates mitochondrial function, as described in my second publication (see Chapter 3), we 
hypothesize that the mitochondrial function is damped in those cells, thereby affecting the 
cellular Ca2+ homeostasis. As an outlook, analysis of the mitochondrial function in those two cell 
lines would yield further insights in the main key players determining the cellular Ca2+ response.  
Ultimately, the changes in Ca2+ concentrations can determine the signaling specificity of 
downstream cascades and their functional outcomes. In more detail, they can activate or inhibit 
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the MAPK cascade by regulating protein-protein interactions and the subcellular localization of 
ERKs (Chuderland and Seger, 2008). In this regard, I could detect a main effect between the two 
cell lines in the MAPK pathway activation following the stimulation with OT. Compared to the 
OTR WT cells, the OTR A218T show lower phosphorylation levels of ERK1/2 both, on a basal level 
and in response to OT. The MAPK signaling cascade is a common pathway that is affected by 
many genetic variants and its dysregulations have been implicated in ASD (Vithayathil et al., 
2018). In addition, it has been shown that the anxiolytic effect of OT is mediated via ERK1/2 
activation (Blume et al., 2008; Jurek et al., 2012). A reduction in the basal as well as the OT-
induced phosphorylation of ERK1/2 might therefore modulate this behavior. Even though anxiety 
does not count as core symptom of ASD, there is comorbidity, especially among children. Around 
80 % of children with ASD have been diagnosed with clinically significant anxiety (Leyfer et al., 
2006). Moreover, anxiety comorbidity is linked to a higher severity of ASD symptoms with 
impaired psychosocial functioning (Gillott et al., 2001; Klin et al., 2007). An increase in social 
abilities of ASD patients upon OT treatment might therefore, at least to some extent, be due to 
its anxiolytic effect.  
Besides other crosstalk signaling cascades, the diminished activation of the MAPK pathway 
affects several downstream transcription factors, which is reflected by the huge amount of 
altered transcripts found in the transcriptome analysis. 7823 significantly differentially expressed 
genes have been uncovered in the RNA sequencing. Many of those genes are implicated in the 
cellular processes that I extensively studied and mentioned above like neuronal morphology, 
mitochondrial functioning, activation of the MAPK pathway, and Ca2+ signaling, as revealed by 
the GO analysis. In line with this data, 429 genes relevant for ASD have been identified 
underscoring the important role of the OTR for the etiology of ASD. 
Since one has to consider that the observed variation in mRNA transcript levels might be 
compensated by regulatory networks (El-Brolosy and Stainier, 2017), future experiments should 
focus on a proteomic characterization. Looking at both, the transcriptome and proteome, will 
give a fundamental insight in the cellular dynamics compared to the rather static genome.  
In addition to that, other methodological approaches encompassing the correction of an already 
existing SNP using the technique of base editing or the use of human tissue biopsies like in the 
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functional study from Füeg et al. could be addressed (Fueg et al., 2019). Given the prevalent 
phenotypic variation and possible opposing mechanisms or combinatory effects of other existing 
SNPs, those strategies cannot completely replace a functional characterizations of single SNPs, 
but extend them in a meaningful way.  
Further experiments targeting the receptor function itself including its regional expression and 
availability at the plasma membrane remain to be assessed. A crystallization of the receptor 
variant for detection of structural differences would yield further information on the receptor 
stability and function. Other interesting parameters are the effects on the interaction of the 
receptor variant with its G proteins as well as how ß-arrestin binding and its subsequent 
internalization are affected by the amino acid exchange.  
Finally yet importantly, all experiments in my studies were performed in vitro. Future 
experiments have to address the validity in vivo. Studying conserved signaling pathways in cell 
lines provides important basic knowledge about cellular mechanisms and reduces the number of 
experimental animals enormously. However, changes in the properties of the cells keeping them 
dividing and growing over time under laboratory conditions have to be considered. Moreover, 
regulations within networks and the synergy between different cell types are neglected and have 
to be addressed separately. Therefore, the transformation into three-dimensional cell culture, 
which mimics tissue- and organ specific architecture and thereby allowing better cell-to-cell 
contact and intercellular signaling networks, would approach this demand. Three-dimensional 
culture models behave more similar to the cells in vivo, and are therefore useful tool in the early 
stage of research (Edmondson et al., 2014). 
In the end, I would like to give some general remarks on SNP-based studies. Indeed, SNPs in the 
OTR gene depict an important factor involved in various psychiatric conditions. However, several 
limitations in SNP studies have to be considered.  
First, there is a strong interaction between polymorphisms and cultural background (Ahsan et al., 
2020). Under these conditions, one has to consider possible varieties in studies depending on the 
ethnicity of the cohort. Besides that, too few studies consult a heterogeneity, such as age, sex or 
intelligence quotient. In line with that, apart from pure genetics, non-genetic mechanisms 
affecting mental illness risk should not be underestimated and carefully assessed as well. This 
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involves intracellular mechanisms like epigenetics but also something impossible to assess by 
looking into a single cell: the personal environment (Edwards and Myers, 2007).  
Finally, empathy is a complex socio-emotional behavior influenced by multiple genes. This single-
gene approach focusing on the OTR gene neglects interactions with other genes involved in the 
social and emotional processing. In addition, most of the psychiatric disorders are likely not 
single-gene disorders that are inherited in a clear recessive or dominant manner. In fact, less than 
one percent of all ASD cases are attributable to a mutation in a single gene (Lewis et al., 2019). 
Actually, more than 800 loci with variants have been identified that increase susceptibility to ASD 
(Sanders et al., 2015). Taken together, although it will not fully explain the heterogeneity and 
multifactorial nature of ASD, the OTR and its coupled pathways are highly related to the 
pathogenesis and therefore a promising treatment option for ASD. 
5.3 Conclusion 
In my thesis, I could extend the network of OTR-coupled signaling cascades involving Ca2+-
dependent signaling, the MAPK pathway and their connection with the transcription factor 
MEF2A. In addition to that, I elucidated the effects following OTR activation on various cellular 
processes, such as neuronal morphology, connectivity, mitochondrial function, and expression of 
target genes. In this context, I could confirm a central role for genetic variations affecting the OTR 
gene. In order to understand the complex role of the OTR in psychosocial disorders and make OT 
a safe treatment option as well as a source of potential biomarkers for an early diagnosis, 
especially in the case of ASD, we need more functional studies addressing genetic variants. 
Understanding the nature of gene variations and their effects on the transcriptome and 
proteome will provide an essential profile contributing to the understanding of phenotypic 
variation. 
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6 Abbreviations 
 
µM Micromolar 
µm Micrometer 
µs Microsecond 
ANOVA Analysis of variance 
ASD Autism spectrum disorder 
ATP Adenosine triphosphate 
BSA Bovine serum albumin 
Ca2+ Calcium 
cAMP Cyclic adenosine monophosphate 
CaN Calcineurin 
cacna1c Voltage-gated L-type calcium channel alpha 1C subunit gene 
CHX Cycloheximide 
CNV Copy number variant 
CO2 Carbon dioxide 
D Aspartate 
DNA Deoxyribonucleic acid 
ECM Extracellular matrix 
E.g. For example (exempli gratia) 
ERK Extracellular signal regulated kinase 
FCCP Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone 
FWHM Full width half maximum 
GWAS Genome-wide association studies 
HEK Human embryonic kidney 
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I.e. That is (id est) 
IHC Immunohistochemistry 
INH Inhibitor 
LTR Long terminal repeat 
MAPK Mitogen-activated protein kinase 
MEF Myocyte enhancer factor 
MEK Mitogen-activated protein kinase kinase 
mM Millimolar 
ms Millisecond 
mV Millivolt 
nM Nanomolar 
Na+ Sodium 
OCR Oxygen consumption rate 
OT Oxytocin 
OTA Oxytocin receptor antagonist 
OTR Oxytocin receptor gene 
OTR Oxytocin receptor 
p Phosphorylated 
PBS Phosphate buffered saline 
PKC Protein kinase c 
rel Relative 
RNA Ribonucleic acid 
S Serine 
scrRNA Scrambled RNA 
SD Standard Deviation 
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SEM Standard error of the mean 
siRNA Small interfering RNA 
SNP Single nucleotide polymorphism 
TBS Tris buffered saline 
TBS-T Tris buffered saline with tween 
TGOT [Thr4,Gly7]-Oxytocin 
trpc Transient receptor potential channel gene 
TRPC Transient receptor potential channel 
VEH Vehicle 
VP Vasopressin 
WB Western Blot 
WT Wildtype 
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